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gradual paralysis and culminating in the inability to breathe or swallow. This neuronal degeneration 
occurs in a spatiotemporal manner from a point of onset in the central nervous system (CNS), suggesting 
that there is a molecule that spreads from cell-to-cell. There is strong evidence that the onset and 
progression of ALS pathology is a consequence of protein misfolding and aggregation. In line with this, a 
hallmark pathology of ALS is protein deposition and inclusion formation within motor neurons and 
surrounding glia of the proteins TAR DNA-binding protein 43, superoxide dismutase-1, or fused in 
sarcoma. Collectively, the observed protein aggregation, in conjunction with the spatiotemporal spread of 
symptoms, strongly suggests a prion-like propagation of protein aggregation occurs in ALS. In this review, 
we discuss the role of protein aggregation in ALS concerning protein homeostasis (proteostasis) 
mechanisms and prion-like propagation. Furthermore, we examine the experimental models used to 
investigate these processes, including in vitro assays, cultured cells, invertebrate models, and murine 
models. Finally, we evaluate the therapeutics that may best prevent the onset or spread of pathology in 
ALS and discuss what lies on the horizon for treating this currently incurable disease. 
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Amyotrophic lateral sclerosis (ALS) is characterized by the progressive degeneration of
the motor neurons that innervate muscle, resulting in gradual paralysis and culminating in
the inability to breathe or swallow. This neuronal degeneration occurs in a spatiotemporal
manner from a point of onset in the central nervous system (CNS), suggesting that
there is a molecule that spreads from cell-to-cell. There is strong evidence that the
onset and progression of ALS pathology is a consequence of protein misfolding and
aggregation. In line with this, a hallmark pathology of ALS is protein deposition and
inclusion formation within motor neurons and surrounding glia of the proteins TAR
DNA-binding protein 43, superoxide dismutase-1, or fused in sarcoma. Collectively,
the observed protein aggregation, in conjunction with the spatiotemporal spread of
symptoms, strongly suggests a prion-like propagation of protein aggregation occurs in
ALS. In this review, we discuss the role of protein aggregation in ALS concerning protein
homeostasis (proteostasis) mechanisms and prion-like propagation. Furthermore, we
examine the experimental models used to investigate these processes, including in vitro
assays, cultured cells, invertebrate models, and murine models. Finally, we evaluate the
therapeutics that may best prevent the onset or spread of pathology in ALS and discuss
what lies on the horizon for treating this currently incurable disease.
Keywords: amyotrophic lateral scelerosis, proteostasis, protein aggregation, prion-like, in vitro models,
invertebrate models, mouse models, therapeutics
INTRODUCTION
Proteostasis and Prion-Like Propagation
A major pathological component of neurodegenerative diseases such as Alzheimer’s disease,
Parkinson’s disease, frontotemporal lobar degeneration (FTLD), and amyotrophic lateral sclerosis
(ALS) is the prion-like propagation of misfolded and aggregated proteins in the central nervous
system (CNS; for recent reviews in each case see—Hock and Polymenidou, 2016; Watts and
Prusiner, 2018; McAlary et al., 2019b; Vargas et al., 2019). The idea of prion-like propagation
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of protein misfolding and aggregation in these diseases offers
a plausible explanation for their idiopathic nature, progressive
anatomical spread, the selective vulnerability of specific CNS
regions, characteristic pathologies, and age-associated onset
(Prusiner, 2001). In each disease, particular proteins are thought
to misfold into a conformation that is capable of propagating
throughout the CNS like the infectious prion protein (PrP;
Vaquer-Alicea and Diamond, 2019).
PrP is typically found in a conformation composed primarily
of alpha-helices (PrPC); however, it can be converted into
a β-sheet-rich pathogenic conformation (PrPSc) that can
recruit and convert normal PrP to become pathogenic PrPSc
through a template-directed manner (Prusiner, 1982; Pan
et al., 1993). This conversion may be the result of aberrant
biosynthesis and processing in cells (reviewed in Chakrabarti
et al., 2009). There is no defined structure for PrPSc as it
exists in a continuum from monomers to large amyloid-like
polymeric assemblies (McKinley et al., 1991; Ceroni et al.,
1996). Similar to PrPSc, proteins implicated in the etiology of
many neurodegenerative diseases are known to form amyloid
in vitro and deposit into intracellular inclusions in an amyloid
conformation (Chiti and Dobson, 2017). The amyloid state
is defined by its cross-β fiber architecture (Eisenberg and
Jucker, 2012; Eisenberg and Sawaya, 2017), and is of critical
importance to the pathogenic mechanisms of prions and
prion-like proteins.
In vitro, the formation of amyloid is thought to proceed
from the initial misfolding and aggregation of protein monomers
into an ensemble of soluble non-native oligomeric states, with
some oligomers forming proto-fibrils capable of elongating
through template-directed monomer addition (Arosio et al.,
2015). Amyloid fibrils are typically highly thermodynamically
stable but vary in their mechanical stability (Yoon et al., 2013).
Amyloid fibrils with low mechanical stability are more likely
to fragment, leading to the exposure of more ends from which
they can elongate in a repetitive cycle of fragmentation and
growth (Knowles and Buehler, 2011; Figures 1A,B). Indeed,
fragmentation is a highly important characteristic of the
infectivity and replication propensity of prions and prion-like
proteins (Marchante et al., 2017). Furthermore, microstructural
heterogeneity in the initial population of misfolded protein and
oligomers is thought to give rise to a range of conformationally
distinct amyloid fibrils with different physical properties, often
termed polymorphs (Petkova, 2005; Kodali et al., 2010; Safar
et al., 2015). Over time, the fibril polymorphs with properties
that permit efficient self-replication are selected for, giving rise
to a dominant ‘‘strain’’ of amyloid fibril (Figure 1A). The
notion of different strains of amyloid and prions provides a
highly plausible explanation for the pathologic and clinical
heterogeneity observed in neurodegeneration, as different strains
can spread and recruit benign substrates at different rates (Telling
et al., 1996; Safar et al., 1998; Morales, 2017). Supporting
this, cryo-electron microscopy of amyloid isolated from human
brain tissue has shown structural diversity in fibrils isolated
from a single person (Kollmer et al., 2019) and in different
neurodegenerative prion-like diseases (Fitzpatrick et al., 2017;
Strohäker et al., 2019).
Although amyloid formation is often simplified as a
relatively rapid kinetic reaction involving only the constituent
amyloidogenic protein (Arosio et al., 2015; Figure 1B), the
in vivo formation of these assemblies is notably slower
and more complex (Owen et al., 2019). This additional
complexity is primarily due to the existence of cellular
mechanisms to maintain protein homeostasis (proteostasis;
Yerbury et al., 2016; Figure 1A). Proteostasis is the concept of
the maintenance of the proteome in the correct concentration
(balance of protein synthesis and degradation), in the correct
conformation (chaperones), and at the right location at the
right time (trafficking). The importance of proteostasis in
neurodegenerative disease is highlighted by the fact that
disturbed proteostasis mechanisms are strongly associated
with aging and neurodegeneration (Cheng et al., 2018;
Kurtishi et al., 2019; Lehtonen et al., 2019; Yerbury et al.,
2020). Mutations can predispose a protein to become more
aggregation prone, and mutations in proteostasis components
can impair proteostasis, where both are capable of leading
to an earlier onset of neurodegenerative disease (Figure 1C).
It is suggested that proteostasis capacity declines with age,
with this being due to a combination of genetic and
environmental factors (Hipp et al., 2019), making efforts into
how determining proteostasis is maintained an important part
of neurodegenerative disease research.
The key parts of the proteostasis network that are related
to protein quality control are molecular chaperones and
protein degradation. Molecular chaperone proteins are found
throughout cell compartments, with the endoplasmic reticulum
(ER) containing many chaperones due to the role it plays
in protein synthesis. Protein disulfide isomerases (PDI) are a
family of molecular chaperone proteins, localized primarily to
the ER, that have oxidoreductase activity, which allows them
to reduce and oxidize disulfide bonds in the proteins they are
chaperoning (Hatahet and Ruddock, 2009). The important role
of PDI’s in chaperoning newly synthesized proteins is signified by
their growing involvement in several neurodegenerative diseases,
including ALS (Perri et al., 2016). Another class of molecular
chaperones are heat shock proteins, which act to prevent protein
misfolding and aggregation by binding unstable proteins to either
aid in their refolding or delivering them to cellular protein
degradation machinery (Goldberg, 2003; Hartl et al., 2011;
Balchin et al., 2016). Some molecular chaperone proteins are also
suggested to aid in the mechanical stabilization of amyloid fibrils
by binding along their solvent-exposed surfaces (Shammas et al.,
2011; Binger et al., 2013; Cox et al., 2018). Molecular chaperones
can even break apart amyloid assemblies (Baughman et al., 2018;
Scior et al., 2018), making them easier to degrade or potentially
promoting their propagation (Jones and Tuite, 2005). If a protein
is terminally misfolded or aggregated, it is delivered to protein
degradationmachinery, such as the ubiquitin-proteasome system
and autophagy-lysosomal system, for proteolytic degradation
(Goldberg, 2003; Yerbury et al., 2016). The ubiquitin-proteasome
degrades misfolded proteins (Kleiger and Mayor, 2014), but is
not capable of dealing with larger aggregates, which are typically
degraded, along with damaged cellular components, through
autophagy (Dikic and Elazar, 2018).
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FIGURE 1 | The relationship between proteostasis and prion-like protein propagation. (A) The proteostasis network (green objects) is composed of molecular
chaperone proteins, degradation pathways (proteasomal and autophagic), and the trafficking of proteins. Chaperones act to protect vulnerable proteins from
becoming misfolded and aggregating, potentially through the amyloid pathway (blue). During seed/aggregate formation, proteins vulnerable to amyloid aggregation
can form polymorphic assemblies through template-directed growth, eventually, elicit different biological and pathological effects dependent on the polymorphic
assembly (strain). Amyloid assemblies are thought to propagate from cell-to-cell through exocytosis in vesicles and exosomes, through membrane breakages,
macropinocytosis, and tunneling nanotubes. Once an amyloid assembly has been transferred to a naive cell, replication continues as the amyloid assemblies can
now recruit vulnerable protein within this cell. (B) In vitro experiments have shown that amyloid formation can be augmented via changes in environmental conditions
or mutations (red) in substrate proteins to become more aggressive. Likewise, the addition of molecular chaperones and/or therapeutics (green), such as small
molecules or antibodies, can suppress amyloid aggregation. (C) Amyloid aggregation in humans is a stochastic process, occurring over long time scales and, in
simplistic terms, is an interplay of proteostasis capacity (green) and protein aggregation propensity (blue). Mutations and/or environmental features can result in both
aggressive aggregation and/or a lower proteostasis capacity, ultimately resulting in earlier disease onset in affected individuals.
The relationship between prion-like propagation and the
proteostasis network is still being elucidated. Although the
proteostasis network acts to suppress protein misfolding and
aggregation, some prion-like particles eventually evade these
defensive systems. Indeed, some prion-like strains may be
resistant to neutralization by proteostasis mechanisms. Over
time, these resistant strains could outcompete other strains,
leading to the formation of the pathology observed post-
mortem. It may well be that the polymorphic amyloid assemblies
currently being identified ex vivo (Fitzpatrick et al., 2017; Kollmer
et al., 2019) represent those that are most capable of inducing
disease and, therefore, may present as viable therapeutic targets
in the face of the extreme patient heterogeneity observed in
neurodegenerative diseases. It is also possible that dynamic
prion-like propagation of misfolded proteins may place further
stress on the proteostatic machinery, resulting in additional
errors or even collapse (Yerbury et al., 2016). A combined
understanding of proteostasis and the prion-like mechanisms
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involved in some conditions could potentially shed further
light on pathogenesis. Therefore, this review focuses on the
examination of both proteostasis and prion-like propagation in
amyotrophic lateral sclerosis, a disease in which there is strong
evidence to suggest a combination of prion-like propagation and
dysfunctional proteostasis is occurring simultaneously.
Amyotrophic Lateral Sclerosis—Pathology
and Genetics Related to Prion-Like
Propagation and Proteostasis
Amyotrophic lateral sclerosis (ALS) is characterized by the
progressive degeneration of motor neurons in both the motor
cortex, brain stem, and spinal cord (Van Es et al., 2017). Motor
symptoms have been observed to occur from a focal point of
onset from which proximal motor neurons become affected in
an orderly manner (Ravits et al., 2007; Ravits and La Spada,
2009). The site of onset can be highly heterogeneous, resulting in
varied symptom presentation, which ultimately leads to difficulty
in making a correct diagnosis (Chiò et al., 2009a). Pathology
is also thought to begin at a focal point within the CNS and,
like other neurodegenerative diseases, is associated with the
deposition of proteins into insoluble inclusions. ALS-associated
inclusions are found primarily within motor neurons, but can
also form in the surrounding oligodendrocytes and astrocytes
(Mori et al., 2008; Zhang et al., 2008; Philips et al., 2013;
Brettschneider et al., 2014; Fatima et al., 2015) as well as
cell populations outside the pyramidal motor system (Geser
et al., 2008; Ince et al., 2011; Braak et al., 2013; Brettschneider
et al., 2013). Histopathological studies have suggested that
the spread of pathology from a focal point occurs through
connected cells in stages (Mori et al., 2008; Brettschneider
et al., 2013), similar to other neurodegenerative diseases and
prion diseases.
The key proteins associated with pathological inclusion
formation are transactive response DNA-binding protein 43
(TDP-43; Arai et al., 2006; Neumann et al., 2006), superoxide
dismutase-1 (SOD1; Shibata et al., 1993), and fused in sarcoma
(FUS; Kwiatkowski et al., 2009; Vance et al., 2009). A significant
majority of ALS cases (∼97%) are associated with TDP-43
positive inclusions, where the remainder are associated with
either SOD1 (∼2%) or FUS (∼1%) inclusions (Ling et al., 2013).
TDP-43 is a DNA/RNA-binding protein that has many functions
in RNA metabolism (Buratti et al., 2001, 2005; Hefferon et al.,
2004; Mercado et al., 2005). FUS is also a DNA/RNA-binding
protein that has functions related to both RNAmetabolism (Belly
et al., 2005; Fujii and Takumi, 2005; Andersson et al., 2008) and
the DNA-damage response (Wang W.-Y. et al., 2013). SOD1 is
the primary antioxidant enzyme of the cell and functions to
convert superoxide anion to less harmful molecular oxygen or
hydrogen peroxide (Mccord and Fridovich, 1969). Importantly,
TDP-43, SOD1, and FUS are capable of forming amyloid fibrils
in vitro (Chattopadhyay et al., 2008; Chen et al., 2010; Nomura
et al., 2014), and there is also strong evidence to suggest that,
for at least SOD1 and TDP-43, they adopt an amyloid formation
in vivo (Kato et al., 2000; Bigio et al., 2013; Robinson et al.,
2013), although there is not yet a consensus as classical amyloid
stains are often negative in ALS cases (Neumann et al., 2006;
Kerman et al., 2010).
The most common identified cause of fALS cases is
hexanucleotide (G4C2) repeat expansions in the C9ORF72 gene,
which result in the transcription of large (tens to thousands of
repeats) hexanucleotide repeat RNA molecules and subsequent
repeat-associated non-AUG (RAN) translation into dipeptide
repeat (DPR) proteins (Freibaum and Taylor, 2017). The DPRs
translated from the G4C2 repeat RNA include Gly-Arg (GA),
Pro-Gly (PG), Pro-Arg (PR), Gly-Ala (GA), and Pro-Ala (PA)
polypeptides. These DPRs are thought to elicit different levels
of toxicity and react differently within the cell based on their
physicochemical properties (Freibaum and Taylor, 2017). For
example, PR and GR repeats are suggested to aberrantly interact
with RNA and nucleolar proteins, resulting in disruption to
ribosomal biogenesis (White et al., 2019). On the other hand,
GA repeats have been suggested to bind and trap multiple
proteins responsible for the trafficking of biomolecules between
the nucleus and cytoplasm (Zhang et al., 2016). Regardless of
the effects of the DPRs, the major pathological hallmark of
C9ORF72-associated ALS remains TDP-43 mislocalization and
aggregation (Cook et al., 2020).
Although TDP-43 mislocalization, phosphorylation, and
aggregation in motor neurons is the major pathological hallmark
of ALS, few patients carry TDP-43 mutations. Similar to most
other neurodegenerative diseases and prion diseases, themajority
of ALS cases are sporadic (sALS), accounting for roughly 90%
of cases. The remaining cases are familial (fALS) and, although
some of the underlying genetic causes remain unidentified,
are typically associated with a family history of the disease
(Taylor et al., 2016). Only ∼5% of patients with fALS carry
TDP-43 mutations, SOD1 accounts for ∼20% of fALS cases,
and FUS accounts for ∼5% (Laferriere and Polymenidou, 2015).
The identification of hexanucleotide repeats in C9ORF72 as
being ALS-causative was a significant discovery to the field
as these mutations account for approximately 40% of fALS
cases (Dejesus-Hernandez et al., 2011; Renton et al., 2011).
Importantly, over 20 fALS-associated genes have been identified,
where these genes are broadly associated with proteostasis
mechanisms including protein degradation, protein production
(RNA metabolism), and protein trafficking (Taylor et al., 2016;
Yerbury et al., 2020). Comprehensive reviews of the genetics and
resulting pathomechanisms of ALS have been reviewed elsewhere
(Matus et al., 2013; Renton et al., 2014; Carrì et al., 2015; Medinas
et al., 2017b; Nguyen et al., 2018; Burk and Pasterkamp, 2019;
Mejzini et al., 2019; Vicencio et al., 2020).
A brief example of the complexity of ALS genetics and
mechanisms can be found with ubiquilin-2 (UBQLN2).
UBQLN2 is an fALS-associated protein responsible for
many interactions that facilitate protein degradation via the
proteasomal and autophagic pathways (Kleijnen et al., 2000; Kim
et al., 2008; N’Diaye et al., 2009). As such, pathogenic mutations
in ubiquilin-2 can result in dysfunctional protein degradation
(Deng et al., 2011; Chang and Monteiro, 2015; Osaka et al., 2016;
Renaud et al., 2019). However, UBQLN2 may also play a role in
the dissolution of the cytoplasmic ribonucleoprotein complexes
known as stress granules (Dao et al., 2018), implicating
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FIGURE 2 | An integrative approach using purified protein to assaying the mechanisms of protein unfolding, aggregation, and prion-like behavior. Once purified,
both wild-type and mutant protein is amenable to a suite of assays that can report on folding stability, function, fibrillation, and structure. Application of such
techniques has allowed for the determination of the effect of the mutation on protein stability and fibrillation, the role of specific domains in fibrillation, and even the
structure of fibrils themselves.
dysfunctional RNA metabolism for UBQLN2 mutants.
Furthermore, mutations in genes such as UBQLN2 may
exacerbate the already metastable supersaturated states of
TDP-43, SOD1, and FUS (Ciryam et al., 2017), hence, leading
to the downstream pathological aggregation of these proteins
in particular.
Collectively, the pathological aggregation and prion-like
spread of specific proteins as a response to numerous potential
mutations in the proteostasis network highlights the critical
relationship between proteostasis and prion-like propagation in
ALS. As such, researchers have exploited various experimental
models to investigate these mechanisms in disease, including
the in vitro study of purified proteins and cultured cells, as
well as in vivo in invertebrate models (Caenorhabditis elegans,
Drosophila melanogaster) and mouse models. For reviews that
incorporate zebrafish (Danio rerio) models, see Babin et al.
(2014), Van Damme et al. (2017), and Morrice et al. (2018).
Here, we focus specifically onmodels that have used either SOD1,
TDP-43, or FUS.
IN VITRO MODELS TO EXAMINE
PROTEOSTASIS AND PRION-LIKE
FEATURES OF AMYOTROPHIC LATERAL
SCLEROSIS
Purified Protein Systems
Much of the knowledge that forms the foundation of our
understanding of proteostasis collapse, and how this may result
in the exponential replication of a prion-like particle in disease,
has been supported and initiated by studies of purified protein.
The simplistic and reductionist nature of experiments using
purified protein affords significant advantages in the specific
elucidation of protein structure and function. Through precise
control and modulation of the environment (temperature,
pH, oxidative/reducing, osmolyte concentration, denaturants)
and the proteins (post-translational modification, mutation,
binding partners, chaperones) in an assay, a more fundamental
understanding of the processes underlying protein misfolding
and prion-like propagation can be achieved.
Superoxide Dismutase-1
As a result of being the first protein found to harbor
ALS-associated mutations (Rosen et al., 1993), SOD1, in its
purified form, has been extensively studied from the perspectives
of protein folding, aggregation, and prion-like propagation
(McAlary et al., 2019b; Wright et al., 2019; Trist et al.,
2020). SOD1 protein is most often expressed and purified
using either bacteria (E. coli) or yeast (S. cerevisiae, Hallewell
et al., 1985, 1987). Considering the extensive post-translational
modification (PTM) that SOD1 must undergo before reaching
its native conformation, which includes metal-binding, disulfide
formation, and N-terminal acetylation, yeast are the expression
vector of choice as this system is capable of imparting all of these
PTMs (Hallewell et al., 1987). A bacterial expression strategy
to facilitate correct metal input and disulfide formation is to
co-express SOD1 with its co-chaperone the copper chaperone
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for SOD1 (CCS) in the presence of excess copper and zinc
(Lindberg et al., 2002).
A SOD1 monomer is an 8-stranded β-barrel with two major
loops, the metal-binding loop (loop IV) and electrostatic loop
(loop VII), being responsible for the coordination of metals
or guidance of superoxide substrate to the enzymatic site,
respectively. Furthermore, a conserved intramolecular disulfide,
that stabilizes the tertiary structure and promotes dimerization,
is formed between residues Cys57 and Cys146 (Wright et al.,
2019). The native conformation of SOD1 is an impressively stable
homodimer, evidenced by resistance to thermal denaturation
and proteolytic digestion (Senoo et al., 1988; Rodriguez et al.,
2002). For this reason, SOD1 homodimers are sometimes
used as a non-aggregating control protein in some assays
(Gregory et al., 2017). Although the native conformation of
SOD1 is highly stable, the maturation (sequential acquisition of
post-translational modifications) folding landscape of SOD1 is
highly susceptible to destabilization and off-folding pathways,
especially when mutated (Lindberg et al., 2002; Rodriguez
et al., 2002; Luchinat et al., 2014, 2017; Sekhar et al., 2015,
2016; McAlary et al., 2016; Culik et al., 2018). Given that
ALS-associated mutations in SOD1 were found to elicit a gain-
of-toxic function effect (Bruijn et al., 1998), and that protein
misfolding and aggregation is a key hallmark of SOD1-associated
ALS (Durham et al., 1997; Shinder et al., 2001), much work
has focused on the effect that ALS-associated mutations had on
SOD1 folding stability (Wright et al., 2019). In particular, studies
have focused on dissecting the differences between mutant and
wild-type SOD1 across its maturation landscape, with a focus on
monomer stability (Lindberg et al., 2005; McAlary et al., 2016)
and dimer stability (Lindberg et al., 2005; Redler et al., 2011;
McAlary et al., 2013; Capper et al., 2018; Chantadul et al., 2020).
Using both wild-type and variants of SOD1 with its free cysteines
replaced (Lepock et al., 1990), SOD1 folding and misfolding has
been rigorously probed via circular dichroism (Lindberg et al.,
2002, 2005; Byström et al., 2010; Wright et al., 2013), nuclear
magnetic resonance (Arnesano et al., 2004; Sekhar et al., 2015,
2016; Culik et al., 2018), and calorimetry (Rodriguez et al., 2002;
Broom et al., 2015, 2016; Anzai et al., 2017).
Some evidence, however, shows that certain ALS-associated
mutations, such as D101N, do not significantly alter the folding
stability of the SOD1 maturation states that are thought to be
likely disease precursors (Byström et al., 2010; Vassall et al.,
2011). Indeed, some mutations confound attempts to directly
relate folding stability to the variable patient survival observed
for patients with different SOD1 mutations (Byström et al.,
2010; Vassall et al., 2011; McAlary et al., 2016). More recently,
the role of macromolecular crowding in tuning protein folding
stability has become clearer. Macromolecular crowding refers
to a high concentration of macromolecules (proteins, nucleic
acids, lipids, carbohydrates) in solution. Contrary to previous
ideas, macromolecular crowding can destabilize proteins that
are typically considered as stable when assessed at dilute
concentrations (Miklos et al., 2011; Sarkar et al., 2012). SOD1 is
no exception to this as evidence is emerging that even wild-type
SOD1, in its metal-free and/or reduced form, is destabilized
at a physiological temperature under crowded conditions (Bille
et al., 2019; Takahashi et al., 2020). Indeed, in-cell nuclear
magnetic resonance experiments of SOD1 have revealed that
destabilization is common to both wild-type and ALS-associated
mutants (Luchinat et al., 2014; Danielsson et al., 2015). In regards
to both proteostasis and prion-like propagation, the consensus
of this work suggests that ALS-associated mutations can have
specific destabilizing effects on SOD1 structure, resulting in a
greater proportion of the protein populating an ensemble of
non-native states and, therefore, is susceptible to aggregation
and prion-like conversion (McAlary et al., 2019b; Wright et al.,
2019). Furthermore, it would be interesting to revisit the
biophysical studies of the effects of ALS-associated mutations
on SOD1 folding stability with our greater understanding
of the effect of macromolecular protein crowders. By better
understanding the effects of protein crowding on SOD1 stability,
we may better understand how specific mutations promote
cytotoxic aggregation and the relationship between SOD1 variant
stability and patient phenotype.
Similar to the above-mentioned studies of SOD1 folding
stability, the examination of the fibrillation of SOD1 has
seen extensive use of purified protein. Due to the high
stability of SOD1, some assays have induced fibrillation of
purified protein using harsh thermal or chemical conditions
(DiDonato et al., 2003; Stathopulos et al., 2003); however,
the most physiologically relevant assays have simply utilized
chelating and reducing conditions to promote SOD1 fibrillation
(Chattopadhyay et al., 2008). Typical SOD1 aggregation assays
induce the fibrillation of the protein under shaking conditions
and measure an increase in β-sheet content using Thioflavin-T
(Naiki et al., 1989). Shaking is considered to increase the rate
at which fibrils fragment to create new ends from which to
polymerize. Although the fibrillation of SOD1 has been described
as being mostly fragmentation-assisted in vitro and in vivo
(Lang et al., 2015), a recent study reported the formation of
SOD1 fibrils under quiescent conditions (Khan et al., 2017),
suggesting alternative pathways by which SOD1 can fibrillate
and that certain strains may be preferentially selected depending
on the method used. Using the Thioflavin-T assay, it has
been shown that even wild-type SOD1, in its demetallated
and reduced form, is capable of forming amyloid fibrils
(Chattopadhyay et al., 2008; Furukawa et al., 2008; Lang et al.,
2012; Chan et al., 2013; Ivanova et al., 2014; Abdolvahabi
et al., 2016; McAlary et al., 2016). Furthermore, ALS-associated
mutations augment the fibrillation of SOD1 to different degrees
(Furukawa et al., 2008, 2010; Lang et al., 2012; Chan et al.,
2013; Abdolvahabi et al., 2016, 2017; McAlary et al., 2016),
whereas some de novo mutations and PTMs have been shown
to prevent (Abdolvahabi et al., 2015; Rasouli et al., 2017;
Pokrishevsky et al., 2018) or enhance fibrillation (Shi et al.,
2013). The Thioflavin-T assay has also been used to examine
if SOD1 fibrillation can be lowered using chaperone proteins
(Yerbury et al., 2013) or small molecules (Bhatia et al., 2015, 2020:
Malik et al., 2019).
N-terminal acetylation of α-synuclein is reported to
significantly alter the secondary structure of the protein
(Trexler and Rhoades, 2012) and therefore, its aggregation
kinetics and structure (Guerrero-Ferreira et al., 2019; Watson
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and Lee, 2019). Importantly, many of the studies examining
SOD1 fibrillation have utilized bacterially expressed protein,
which is not N-terminally acetylated like it is typically found
in eukaryotic systems. Although no direct comparisons have
been performed between N-terminally acetylated SOD1 and
non-acetylated SOD1, there are some notable differences
in the identified cores of the amyloid fibril structures
produced by the two forms (Furukawa et al., 2010; Chan
et al., 2013). There is currently no high-resolution structure
of SOD1 fibrils composed of the full-length protein, unlike
tau (Fitzpatrick et al., 2017), α-synuclein (Li B. et al., 2018),
and amyloid-β (Schmidt et al., 2015). Current high-resolution
structures of SOD1-related fibrils are restricted to synthetically
produced peptides of small amyloidogenic regions of
the protein (Ivanova et al., 2014; Sangwan et al., 2017).
The amyloidogenic regions of SOD1 are 14VQGIINFE21,
30KVWGSIKGL38, 101DSVISLS107, and 147GVIGIAQ153
(Ivanova et al., 2014). However, limited proteolysis of
fibrils produced from recombinant SOD1 has identified the
N-terminus of the protein, comprising residues 1–63, as the
potential amyloidogenic core (Furukawa et al., 2010; Chan
et al., 2013). Other regions of the SOD1 molecule have also
been detected, suggesting polymorphism in the fibril structures
generated. It would be valuable to determine the structure of
SOD1 fibril polymorphs to understand better the relationship
between SOD1 aggregation and the prion-like spread observed
in patients.
Protein fibrillation assays have been a key tool in
understanding the underlying prion-like propagation of
SOD1 aggregation. The presence of seed in fibrillation assays
essentially bypasses the need for the nucleation of a fibrillation-
competent protein assembly in the assay, thus shifting the
kinetics almost entirely to fibril elongation (Cohen et al., 2011).
Through the addition of preformed protein aggregates (from
recombinant sources, cells, or whole organisms) to fibrillation
assays, it can be elucidated whether or not the seed is present
within a sample (Schmitz et al., 2016), the susceptibility of
protein variants to seeded fibrillation (Pokrishevsky et al.,
2018), or the ability of different treatments to prevent seeded
fibrillation (Sievers et al., 2011). Indeed, the first evidence that
SOD1 may have prion-like properties first came from fibrillation
assays of recombinant purified SOD1 seeded with spinal
cord extracts from mice overexpressing human SOD1-G93A
(Chia et al., 2010). From seeded fibrillation assays, it has
been determined that loss of the intramolecular disulfide is
a significant contributor to increasing the susceptibility of
SOD1 to undergo seeded fibrillation (Chattopadhyay et al., 2015)
and that this is enhanced by mutation. Other studies examining
the seeded fibrillation of SOD1 have shown that some de novo
mutants of SOD1 are resistant to seed-induced fibrillation
(Pokrishevsky et al., 2018), and that specific amyloidogenic
segments of SOD1 contribute more significantly to seeded
aggregation (Ivanova et al., 2014).
Overall, it is clear that ALS-associated mutations in
SOD1 lower the folding stability of the protein and permit
the sampling of more aggregation-prone conformations. These
destabilized conformations are capable of both nucleating the
formation of amyloid fibrils and acting as a substrate for
the further polymerization of existing fibrils. Future inquiries
in this area focusing on the elucidation of the structure
and polymorphism of SOD1 fibrils would be useful to not
only understand the fibrillation of SOD1 but also to design
therapies that may prevent it. Besides, advances in the sensitivity
of detecting fibrillar species with prion-like properties from
clinical sources using fibrillation assays (also called the real-time
quaking-induced conversion assay; Schmitz et al., 2016) is
currently unexplored for SOD1-associated ALS and ALS in
general. Application of the sensitivity of the Thioflavin-T-based
fibrillation assays to ALS patient tissue would be invaluable in
elucidating the relationship between patient prognosis and the
prion-like nature of the disorder.
Transactive Response DNA-Binding Protein 43
There has been less research performed utilizing recombinant
purified TDP-43, which is primarily due to the difficulty
in purifying soluble TDP-43, and the difficulty handling the
purified product. Some advances have recently been made in this
space with the usage of solubility tags, replacement of tryptophan
residues with alanine, and exhaustive processing of recombinant
protein extracts (Li et al., 2017; Vivoli Vega et al., 2019; Wright
et al., 2020). Owing to the difficulty associated with purification
of the full-length protein, the biophysical understanding of
TDP-43 has been obtained predominantly by analyses of purified
single domains of the protein, including the N-terminal domain
(NTD; Kuo et al., 2009; Mompeán et al., 2016), RNA-recognition
motifs (RRM1 and RRM2; Kuo et al., 2009; Lukavsky et al., 2013),
and the C-terminal low-complexity domain (LCD; Conicella
et al., 2016). The intrinsically high aggregation propensity of the
LCD is likely why the examination of full-length TDP-43 has
been difficult, as other domains are reported to be soluble when
expressed in heterologous systems (Kuo et al., 2009; Lukavsky
et al., 2013; Mompeán et al., 2016). As well as affording TDP-43
a high propensity to aggregate, the LCD is also the domain that
contains the majority of ALS/FTLD-associated mutations (Abel
et al., 2013) and forms the major component by mass of the
ALS/FTLD-associated fragments of TDP-43 (Neumann et al.,
2006). As such, the LCD has been a primary focus of TDP-43-
focused ALS/FTLD research.
The TDP-43 LCD is defined as a prion-like domain due to
its enrichment in asparagine, glutamine, glycine, and tyrosine
residues, making it similar in sequence composition and
physicochemical properties to the yeast prion protein Sup35
(King et al., 2012). Recent studies have highlighted the capability
of low-complexity domains in DNA/RNA-binding proteins
(not all of them prion-like) to facilitate the formation of
physiologically relevant biomolecular condensates through the
process of liquid-liquid phase separation (LLPS) in vitro (Banani
et al., 2017). Evidence for in vivo formation and dysfunction
of biomolecular condensates is starting to emerge (Zhang
et al., 2020). The TDP-43 LCD has been shown to undergo
LLPS, with this being primarily mediated by a transiently-
populated α-helix (residues 321–330; Conicella et al., 2016)
as well as aromatic residues spread throughout the domain
(Li H.-R. et al., 2018). The majority of ALS/FTLD-associated
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mutations in TDP-43 are localized to the LCD. Considering
this, a recent effort has been applied to examining the role of
biomolecular condensates, such as stress granules, as a potential
site in which the initial aggregation of TDP-43 (and other
RNA-binding proteins) may occur (reviewed in Nedelsky and
Taylor, 2019). In vitro evidence suggests that LLPS of the TDP-43
LCD promotes amyloid fibril formation, likely at the condensate-
solution interface (Babinchak et al., 2019) however, whether
these fibrils are formed within condensates remains unclear.
It is thought that disease-associated mutations may exacerbate
the gradual loss of internal molecular rearrangement within
condensates and promote a liquid-to-solid transition of the
protein components, although this hypothesis is currently not
fully tested, especially in regards to amyloid formation, and
requires further investigation in both protein only assays and
living cells.
Although the relationship between TDP-43 LCD LLPS and
aggregation is not well understood, the capacity of the TDP-43
LCD, and smaller segments of it, to form amyloid fibrils in vitro
is well-established (Chen et al., 2010; Guo et al., 2011; Jiang et al.,
2013, 2016; Mompeán et al., 2014; Sun C.-S. et al., 2014; Zhu
et al., 2014; Babinchak et al., 2019; Cao et al., 2019). Cross-β
fibers are formed by several small segments of the TDP-43 LCD
(Guenther et al., 2018a) whichmay comprise the cores of amyloid
polymorphs formed by larger segments and the entire LCD itself
(Chen et al., 2010; Guo et al., 2011; Jiang et al., 2013, 2016;
Mompeán et al., 2014; Babinchak et al., 2019; Cao et al., 2019;
Shenoy et al., 2020). Cryo-electron microscopy has been utilized
to examine the polymorphic nature of synthetic TDP-43 LCD
segment assemblies composed of amino acid residues 311–360 or
286–331 (Cao et al., 2019). Although these structures are the
result of in vitro assays of LCD segments, they provide a starting
point by which to understand the amyloid state of TDP-43 and
how it might confer different pathogenic severities in patients.
Indeed, it is clear that TDP-43 can adopt an amyloid-like state in
relevant tissues from ALS and FTLD patient samples as shown
by immunoelectron microscopy (Lin and Dickson, 2008; Thorpe
et al., 2008) and Thioflavin-S staining of carefully processed
samples (Bigio et al., 2013; Robinson et al., 2013). It is important
to note that confirmation of amyloid in tissue samples has
classically relied upon Thioflavin-S and Congo-red staining,
however, evidence has emerged that in some cases protein fibrils
may not effectively bind these dyes (Wang Y.-T. et al., 2013;
Rasouli et al., 2017), making electron microscopy the tool of
choice to definitively assess aggregate morphology (amorphous
or fibrillar).
Unlike the LCD, the TDP-43 NTD is a well-structured and
stable domain (Qin et al., 2014; Mompeán et al., 2016) that is
capable of undergoing extensive multimerization (Chang et al.,
2012) and polymerization (Afroz et al., 2017; Mompeán et al.,
2017; Tsoi et al., 2017; Wang et al., 2018) in vitro. These
biophysical studies, using measures of stability, protein-protein
interactions, and structural techniques, have suggested several
roles for the NTD in both TDP-43 function and pathology.
Namely, the NTD promotes the formation of TDP-43 dimers
and multimers, likely through head-to-tail interactions (Afroz
et al., 2017; Wang et al., 2018; Wright et al., 2020; although there
is a dispute about the contact interfaces). The NTD-mediated
interaction of separate TDP-43 molecules may prevent the
interaction of the aggregation-prone LCDs between interacting
TDP-43 molecules (Afroz et al., 2017), suggesting a protective
role for the NTD in ALS/FTLD. This notion of NTD-derived
protection is supported by the cleavage of the NTD to give rise
to C-terminal pathological fragments of TDP-43 in ALS/FTLD
(reviewed in Berning and Walker, 2019). In contrast, others
have suggested that NTD-mediated interactions promote the
association and subsequent aggregation of the TDP-43 LCD
(Tsoi et al., 2017).
Similar to the NTD and LCD, the biophysical study of the
TDP-43 RRMs has resulted in furthering the understanding
of how TDP-43 may gain pathogenic properties through
misfolding. A key finding from biophysical analyses of purified
RRM domains or full-length TDP-43 is that DNA/RNA-
binding to the RRMs increases their stability and decreases
the propensity of TDP-43 to aggregate (Huang et al., 2013;
Sun Y. et al., 2014; Zacco et al., 2018, 2019). This information
highlights the importance of the RRMs in understanding TDP-43
proteinopathy and also provides a means for which potential
therapies may be explored by using DNA/RNA oligos to
stabilize cytoplasmic TDP-43, a strategy that is currently being
pursued (Mann et al., 2019). However, some care must be
taken, as the disease-associated D169G mutation that occurs
within RRM1 of TDP-43 has been shown to increase the
stability of the domain but make TDP-43 more susceptible to
caspase-mediated cleavage (Chiang et al., 2016). It is currently
unknown what effect RNA/DNA-binding has on the proteolytic
cleavage of TDP-43. RRM2 of TDP-43 has also been examined
concerning its potential amyloidogenic properties, with data
suggesting that it may play an active role in TDP-43 aggregation
and amyloid formation. Most studies of the amyloidogenic
properties of TDP-43 RRM2 have used small synthetic peptides
of the domain (Saini and Chauhan, 2011, 2014; Wang Y.-
T. et al., 2013; Shimonaka et al., 2016; Guenther et al., 2018b),
but some work has investigated the ability of the entire
RRM2 domain to form amyloid (Shimonaka et al., 2016;
Garnier et al., 2017).
Collectively, this evidence supports a role for RRM2 in
the fibrillation of TDP-43, however, there are still unanswered
questions. The use of small peptides, whilst informative, is not
suitable for the examination of the heterotypic interactions that
typically underlie the formation of diverse fibril polymorphs
(Fitzpatrick et al., 2017; Li B. et al., 2018; Guerrero-Ferreira
et al., 2019; Kollmer et al., 2019). Considering the number
of potential amyloidogenic regions proposed in the TDP-43
LCD (Guenther et al., 2018a), and potential amyloid properties
of RRM2, it may well be that the number of possible fibril
polymorphs formed by heterotypic interactions within TDP-43
is substantial. Furthermore, the disease-associated truncation
of TDP-43 into C-terminal fragments may further diversify
the amyloid structures that it can form. This being said,
small peptides do give the advantage of allowing for the
examination of the seeding properties of highly structurally
pure amyloid samples. This has been demonstrated by using
fibrils formed from small segments of the TDP-43 LCD to
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seed TDP-43 aggregation in cultured overexpressing TDP-43
transgenes (Shimonaka et al., 2016).
Fused in Sarcoma
Like TDP-43, purified FUS protein has not been as well explored
compared to studies of purified SOD1. The N-terminus of FUS
is a functional prion-like domain, followed by several RGG rich
regions encompassing a single RRM, a zinc finger domain, and
finally a nuclear localization signal at the far C-terminus (Iko
et al., 2004). Most purification strategies involve the expression
of FUS in bacteria as a fusion to tags (sometimes fluorescent
and/or solubilizing) on either the N- or C-terminus (Han et al.,
2012; Kato et al., 2012; Kwon et al., 2013; Nomura et al., 2014;
Patel et al., 2015; Monahan et al., 2017; Alberti et al., 2018;
Hofweber et al., 2018; Maharana et al., 2018; Qamar et al., 2018;
Murthy et al., 2019).
Also similar to TDP-43, a focus has been placed on
the ability of FUS to undergo LLPS to form biomolecular
condensates or hydrogels (Han et al., 2012; Kato et al., 2012;
Kwon et al., 2013; Patel et al., 2015; Monahan et al., 2017;
Alberti et al., 2018; Hofweber et al., 2018; Maharana et al.,
2018; Qamar et al., 2018; Murthy et al., 2019). The ability
of FUS to undergo LLPS in vitro can be enhanced by the
ALS-associated G156E mutation (Patel et al., 2015), or it
can be suppressed by chaperones and/or post-translational
modifications (Monahan et al., 2017; Hofweber et al., 2018;
Qamar et al., 2018). Concerning proteostasis, these findings
suggest that the aberrant condensation of FUS, or simply
condensation of FUS disease mutants, may result in the
formation of FUS aggregates in disease. Indeed, FUS condensates
are suggested to solidify (mature) over time and also perhaps
form larger fibrous structures (Patel et al., 2015), although some
work has suggested that careful control of in vitro conditions
(removal of bubbles, usage of unscratched surfaces) prevents
excessive FUS fibril formation in condensation experiments
in vitro (Alberti et al., 2018).
Indeed, current understanding of ALS as a prion-like disorder
is supported strongly by experimentation of both SOD1 and
TDP-43, however, experimentation with FUS is in early stages
(McAlary et al., 2019b). Experiments examining only smaller
regions of FUS, including the RGG-rich regions and the
N-terminal prion-like domain, have established the ability of
FUS to form labile amyloid-like fibers, distinguished from
typical amyloid by their lower thermal stability (Kato et al.,
2012; Murray et al., 2017; Hughes et al., 2018). Also, initial
experiments examining the amyloidogenicity of purified FUS
found that GST-tagged full-length FUS protein showed very
rapid increases in solution turbidity, suggesting that LLPS was
potentially occurring here rather than aggregation (Nomura
et al., 2014). Nomura et al. (2014) also show GST-tagged FUS-
G156E samples were Thioflavin-T positive and that fibrils were
present by electron microscopy, but it is unclear if these were
labile amyloid-like structures or bona fide highly stable amyloid.
In the future, experiments designed to examine if a population
of the amyloid assemblies formed by purified FUS (whether
through LLPS or simple agitation assays) is resistant to detergent
denaturation and proteolytic degradation would be useful to
determine if purified FUS can form pathogenic amyloids. For a
visual summary of the assays that can be performed with purified
protein, see Figure 2.
Cultured Cells
Although studies utilizing purified protein have provided
substantial insight into themisfolding, chaperoning, and amyloid
aggregation of ALS-associated proteins, there is a significant
lack of biological complexity in these systems. Cultured cells, in
the form of immortalized cell lines, have formed a foundation
for understanding proteostasis and prion-like propagation in
ALS/FTLD. The types of systems used are diverse in their design
and application, so we have elicited to focus primarily on those
systems that have best helped understand protein homeostasis
and prion-like propagation within the cellular environment
(reviews on iPSC culture modeling of ALS see Guo et al., 2017;
Van Damme et al., 2017).
Standard cell lines in any biological experimentation
involving ALS/FTLD often include human embryonic kidney
cells (HEKs—often various clones), HeLa cells, SH-SY5Y cells,
Neuro-2a, and NSC-34, however, other cell lines are used too.
NSC-34 cells are a hybrid cell line generated from a fusion of
murine neuroblastoma cells and murine embryonic spinal cord
enriched in motor neurons (Cashman et al., 1992), making
them a particularly useful immortalized model for studying
ALS/FTLD.
Chosen cell lines are often genetically manipulated to
express mutant forms of ALS/FTLD-associated proteins via
transient transfection methods. This has several advantages over
examining endogenous proteins as it allows for the delivery
of mutant genes, fusion constructs, and overexpression. A
common strategy involves the use of fluorescently tagged
SOD1 mutants (Turner et al., 2005; Prudencio et al., 2009;
Stevens et al., 2010; Münch et al., 2011; Polling et al., 2014;
Farrawell et al., 2015, 2019; McAlary et al., 2016; Ayers et al.,
2017; Pokrishevsky et al., 2017, 2018; Zhong et al., 2017; Crosby
et al., 2018), TDP-43 mutants and fragments (Zhang et al., 2009;
Yang et al., 2010; Walker et al., 2013; Farrawell et al., 2015;
Zeineddine et al., 2017; Chen and Cohen, 2019; Chen et al.,
2019; Sackmann et al., 2020), and FUS (Mastrocola et al., 2013;
Britton et al., 2014; Yang et al., 2014; Farrawell et al., 2015;
Patel et al., 2015; Bogaert et al., 2018; Maharana et al., 2018).
Genetically encoded fluorophore tags, such as green fluorescent
protein (GFP), are a highly useful method to specifically
interrogate a protein of interest in cells (Day and Davidson,
2009), and have formed an important part of understanding
the dynamics of ALS/FTLD mutant proteins in the
physiologic environment.
At least for SOD1, there is good evidence to suggest that
the fusion of GFP to it’s C-terminus does not significantly
augment its ability to fold or dimerize (Stevens et al., 2010).
Folding or dimerization of tagged TDP-43 or FUS has not
been assessed; however, fluorescent protein-tagged versions
of either of these proteins appear to localize correctly in
cells, suggesting that tagging is not overly detrimental. Some
researchers use smaller non-fluorescent affinity tags to overcome
non-physiological interactions induced by fluorescent protein
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FIGURE 3 | Understanding protein aggregation and prion-like spread using cultured cells. Cultured cells are amenable to genetic manipulation via transient or
stable transfection, or gene editing to express fluorescently tagged wild-type or mutant forms of proteins. Cultured cells are used to study the ability of cells to uptake
preformed protein aggregates in the form of purified aggregates, aggregates from other cultures, or extracts from organisms. Spreading of prion-like particles can
also be assayed by serial passage of conditioned media, axonal spread through the use of microfluidic co-cultures. Furthermore, cultured cells are amenable to
multiple types of omics that can provide information on wide-scale alterations to the proteome or transcriptome.
tags. Another advantage associated with fluorescent protein
tagging of aggregation-prone proteins is that the localization
of proteins into inclusions can sometimes mask epitopes
detected by commercial antibodies (Prudencio and Borchelt,
2011). Since the fluorescent protein itself is incorporated into
protein inclusions when tagged to aggregation-prone proteins,
it is much easier to ascertain the presence of inclusions in
cell populations using this system. One can then effectively
utilize fluorescence microscopy or flow cytometry to detect
the presence of fluorescent protein inclusions within cells
(Ramdzan et al., 2012), or from cell extracts (Whiten et al., 2016;
Zeineddine et al., 2017).
An advantage of fluorescent tagging of aggregation-prone
proteins in cells is the capability to perform biophysical analyses
by exploiting the photophysical properties of the fluorophore
itself, such as fluorescence recovery after photobleaching (FRAP;
Axelrod et al., 1976) or fluorescence loss in photobleaching
(Lippincott-Schwartz et al., 2003). A major disadvantage of
immunodetection using either affinity epitopes or endogenous
epitopes is that this requires the fixation of cells, making it
challenging or impossible to analyze dynamic events. Combined
usage of both fluorescent tagging and FRAP has revealed
that specific aggregation-prone proteins can localize to distinct
inclusion types (Kaganovich et al., 2008) and that the mobility
of SOD1, TDP-43, and FUS in and outside inclusions and
other compartments can be examined using photobleaching
(Matsumoto et al., 2005, 2006; Weisberg et al., 2012; Farrawell
et al., 2015, 2018; Park et al., 2017).
Key findings from the usage of fluorescently tagged SOD1 in
immortalized cell lines related to protein homeostasis include
that: (1) disease-associated mutant forms of SOD1 are
significantly more aggregation-prone than wild-type SOD1
(Prudencio et al., 2009; Prudencio and Borchelt, 2011;
McAlary et al., 2016; Ayers et al., 2017; Crosby et al., 2018;
Pokrishevsky et al., 2018; Farrawell et al., 2019; Crown
et al., 2020); (2) SOD1 mutants are a target of ubiquitin
proteasome degradation and partition exclusively to the
juxtanuclear quality control compartment that triages proteins
for proteasomal degradation (Matsumoto et al., 2005, 2006;
Weisberg et al., 2012; Farrawell et al., 2015; Ayers et al., 2017;
Park et al., 2017); and (3) the aggregation and associated
toxicity of SOD1 mutants can be alleviated via overexpression
of components of the cellular quality control machinery or
small molecules (Walker et al., 2010; Xia et al., 2011; Park
et al., 2017; Pokrishevsky et al., 2017, 2018; Farrawell et al.,
2019). For TDP-43 and FUS, fluorescent tagging has been
similarly successful, especially when examining the dynamics
of FUS and TDP-43 biomolecular condensates (Patel et al.,
2015; Maharana et al., 2018; Qamar et al., 2018; Gasset-Rosa
et al., 2019; Mann et al., 2019). Considering the growing
understanding of the number of diverse and transient structures
formed in cells (Nedelsky and Taylor, 2019), experiments
investigating protein aggregation in cells must be carefully
interpreted when examining fixed samples. What is thought
to be an aggregate may simply be a transient structure in
some cases.
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FIGURE 4 | Invertebrate models of protein aggregation disorders. Invertebrate models are cheap and efficient systems that are highly amenable to genetic
manipulation through the delivery of transgenes in the forms of human genes or fluorescent proteins, as well as knockout of endogenous genes. The short lifespan of
these models makes them a powerful tool for assaying development and aging. Behavioral analysis can be performed to determine the effect of protein aggregation
in these models, linking observed pathology to clinical phenotypes. Last, these models are highly accessible to imaging and provide access to well-understood
neuroanatomy to assay prion-like spread.
Immortalized cell lines are a highly useful model to
examine the prion-like propagation of protein misfolding and
aggregation in cells, particularly when paired with purified
protein samples. Indeed, a combination of transiently expressed
GFP-tagged SOD1 variants, and in vitro aggregated purified
SOD1 protein was utilized to determine the prion-like properties
of SOD1 aggregates (Münch et al., 2011). The ability to use
exogenous aggregates that can be pure amyloidogenic peptides
from a protein, or have the amyloidogenic region(s) deleted,
is a powerful assay for understanding the structure-function
relationship of prion-like proteins. As such, this system has
been used to examine the seeding of GFP-tagged TDP-43 by
various exogenously added TDP-43 peptide-derived amyloid
fibrils (Shimonaka et al., 2016) or fibrils composed of full-length
TDP-43 (Furukawa et al., 2011). The power of assays that
utilize transgene expression of proteins in cultured cells is
exemplified by the ability to seed aggregation of the reporter
proteins via the addition of samples from human or animal
in vivo sources (Nonaka et al., 2013; Pokrishevsky et al., 2017;
Porta et al., 2018; Laferrière et al., 2019). Furthermore, the
capability of prion-like proteins to replicate and infect can be
easily examined in cells by the simple passage of the conditioned
media to new naive cultures as has been shown for prion-like
SOD1 conformations (Grad et al., 2014). This spread of protein
aggregates between cultured cells can be examined by using dual
fluorescent reporter, or split reporter, strategies. In these assays,
two separate populations of cells are respectively transfected
with prion-like proteins with different color fluorescent tags
or split fluorescent/luminescence tags. Mixing of the separate
cell populations and subsequent co-culturing allows for protein
transfer between the populations which can be detected using
fluorescencemicroscopy, flow cytometry, or a plate reader (Feiler
et al., 2015; Zeineddine et al., 2017; Sackmann et al., 2020). For a
visual summary of the assays that can be performed with cultured
cells, see Figure 3.
To complement tractable and scalable cell-based experiments,
animal experiments are required to examine the effect
of prion-like protein aggregation on physiology and
disease pathogenesis.
INVERTEBRATE MODELS OF ALS
The genetic power and experimental tractability of small animal
models (worm, fly, and fish) provide unique opportunities
to investigate the pathological role of ALS-associated protein
aggregates. Here we will discuss models for neurodegeneration
using Caenorhabditis elegans and Drosophila melanogaster,
focusing on insights gained on pathological mechanisms of
SOD1, TDP-43, and FUS concerning proteostasis mechanisms
and prion-like propagation.
Caenorhabditis elegans
The nematode (roundworm)C. elegans has been used for decades
in the study of neuronal development (Sulston et al., 1983),
anatomy (White et al., 1986), and cellular/molecular function
(Hobert, 2013; Walker et al., 2019). This extensive study has
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led to C. elegans becoming one of the most well-characterized
experimental nervous systems, being the only adult animal for
which the synaptic connectivity of all its∼300 neurons is known
(Cook et al., 2019). More recently, the worm model has become
increasingly popular for studies of neurodegeneration and
pathology, in part due to its short lifespan (2–3 weeks), genetic
tractability, transparent nature, amenability to high-throughput
genetic or pharmacological screens (Kaletta and Hengartner,
2006), and the fact that >80% of the C. elegans proteome has
human homologs (Lai et al., 2000). In particular, the genetic
accessibility of C. elegans permits the rapid generation of
transgenic lines (within 1–2 weeks) with expression restricted
to specific cells or tissues, including the remarkable ability to
express transgenes in individual neurons. Also, the transparent
nature of C. elegans enables imaging of fluorescence-tagged
proteins in specific tissues/cells within a whole organism
(Heppert et al., 2016), which has been invaluable in making
mechanistic links between protein aggregation and behavioral
deficits. Moreover, the short lifespan ofC. elegans facilitates aging
experiments to be performed rapidly and cost-effectively.
In this section, we will focus on studies that use C.
elegans transgenic lines to investigate the mechanisms through
which ALS-associated mutations in SOD1, TDP-43, and FUS
contribute to protein aggregation, neurodegeneration, and
behavioral defects concerning proteostasis mechanisms and
prion-like propagation. Other aspects of ALS (and other
neurodegenerative disease) pathology are covered in detail in
reviews elsewhere (Dimitriadi and Hart, 2010; Li and Le, 2013;
Therrien and Parker, 2014).
Superoxide Dismutase-1
Most studies of SOD1 using C. elegans involve the transgenic
expression of human wild-type (WT) or mutant SOD1 (hSOD1)
tagged with fluorescent proteins to facilitate visualization
of protein localization (i.e., whether diffuse in the cell or
aggregated). These studies have shown that expression of disease-
associated mutant forms of SOD1 (usually G85R, G93A) is
associated with increased aggregation and behavioral deficits.
The formation of aggregates during aging is correlated with
defects in the proteostasis network (Hipp et al., 2019). For
example, expression of hSOD1-G85R in all neurons resulted
in locomotor deficits and inclusion-like structures of hSOD1-
G85R-YFP (yellow fluorescent protein) in the cell bodies of
motor neurons along the ventral nerve cord, observed via
fluorescence microscopy and electron microscopy (Wang et al.,
2009a). These observations correlated with reduced numbers,
fluorescence intensity, and motility of pre-synaptic markers such
as GFP-tagged synaptobrevin. Interestingly, despite hSOD1-YFP
fluorescence being observed in most neurons, some individual
neurons did not display aggregates at the fourth larval stage
(the last larval stage before the adult moult; Wang et al.,
2009a), although later time points were not analyzed in this
study. This indicates that there are neuron-subtype-specific
differences in how misfolding-prone SOD1 is sequestered in
individual cells. Interestingly, expression of human SOD1
(hSOD1) mutants G85R, G93A, and G127X in C. elegansmuscle
showed limited toxic effects (after assaying motility, myofilament
organization, muscle development, and egg-laying) despite
all hSOD1(mutant) lines showing clear aggregate formation
(Gidalevitz et al., 2009).
Wang et al. (2009a) used their hSOD1 C. elegans model
to perform a genome-wide RNAi screen for genes that when
knocked down led to an increase in fluorescence aggregates;
these genes were therefore postulated to normally suppress or
delay aggregation formation. Eighty-one hits were identified,
of which 27.2% were factors involved in proteostasis (protein
chaperones, misfolding, and turnover) including heat shock
factor 1 (HSF1), Hsp110, a DnaJ family member A2 (DNJ-19), an
Hsp70 family member (STC-1), E3 ubiquitin ligase components
SEL-10 and RBX-1, and proteins involved in SUMOylation
[small ubiquitin-like modifiers (SUMOs)] UBC-9 and GEI-17.
Several of these hits were validated through genetic crosses (see
Wang et al., 2009a for details).
Later studies examining the effects of transgenic
hSOD1-G93A expression in GABAergic motor neurons of the
ventral nerve cord (using the unc-25 promoter) confirmed earlier
findings, showing that expression of GFP-tagged hSOD1-G93A
is correlated with reduced locomotion and the formation of
large aggregates (Li et al., 2013, 2014). Interestingly, critical
defects were observed to a similar extent in hSOD1-WT and
hSOD1-G93A transgenic lines, such as age-dependent locomotor
dysfunction and motor neuron degeneration; hSOD1-WT also
formed aggregates in motor neurons—albeit to a lesser extent
than hSOD1-G93A (Li et al., 2014). As toxicity associated
with hSOD1WT expression was not observed in the hSOD1
pan-neuronal lines (Wang et al., 2009a), these authors suggested
that motor neurons may be more susceptible to hSOD1-linked
toxicity, or that their transgene expression levels were simply
higher compared with pan-neuronal lines. In both hSOD1WT
and hSOD1-G93A lines, cell-autonomous over-expression
of key autophagy initiator UNC-51 partially alleviated axon
guidance defects observed with hSOD1 expression (Li et al.,
2014). UNC-51 is required for proper localization of the Netrin
receptor UNC-5, a critical player in axon guidance (Ogura and
Goshima, 2006), which may explain its involvement in this
phenotype—although a role specifically in autophagy has not yet
been explored.
Conventional microinjection protocols for generating
transgenic C. elegans result in the formation of multi-copy
transgene arrays (Mello et al., 1991), which express at high
levels. Over-expression of hSOD1 has been linked to deleterious
effects even for wild-type hSOD1 in C. elegans (Li et al.,
2014). This makes it challenging to differentiate the effects
of protein overexpression from that of ALS mutations, or
to identify interventions that address one or the other.
To overcome this issue, Baskoylu et al. (2018) generated
single-copy insertions of C. elegans wild-type SOD-1 and
A4V, H71Y, and G85R mutants (by comparison of C. elegans
and human SOD1 sequences) via Mos1-mediated single copy
insertion (MosSCI). Toxic effects were more subtle in MosSCI
transgenic lines compared with conventional multi-copy
arrays expressing hSOD1 (Baskoylu et al., 2018). One of the
most pronounced effects was the formation of hSOD1WT-
YFP inclusions when this transgene was co-expressed in the
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same neurons expressing single-copy insertions of mutant
C. elegans SOD-1 (ceSOD1): single-copy insertions of mutant
ceSOD1 showed significantly higher hSOD1WT-YFP inclusions
compared with ceSOD1WT or the empty vector control. The
authors theorize that the hSOD1WT-YFP inclusions were
possibly seeded by misfolded mutant C. elegans SOD1 protein
in MosSCI models, suggesting a prion-like propagation effect
(Baskoylu et al., 2018).
Mislocalization of SOD1 to the nucleus is linked to
toxicity (Gertz et al., 2012). Mutations introduced in SOD1 to
disrupt the consensus Nuclear Export Signal (NES) showed
nuclear localization of GFP/YFP-tagged SOD1 in cultured cells
and C. elegans neurons (Gertz et al., 2012). Although the
NES-disrupting mutation L42Q by itself did not cause severe
lifespan defects, in combination with the G85R mutation,
expression of hSOD1L42Q/G85R in C. elegans neurons led to
significantly reduced lifespan compared with hSOD1WT controls
(Zhong et al., 2017).
Transactive Response DNA-Binding Protein 43
C. elegans is an excellent model system to assess prion-like
spreading due to its well-defined, stereotyped anatomy and
transparent nature, enabling the visualization of fluorescently
tagged proteins across multiple tissues in a living organism
(Nussbaum-Krammer and Morimoto, 2014). Like for SOD1,
numerous studies have used overexpression of wild-type or
ALS-linked variants of human TDP-43 (hTDP-43) to model
aspects of pathology in C. elegans. Pan-neuronal expression
of YFP-tagged hTDP-43(WT), ALS-associated mutant forms
(Q331K and M337V), or the C-terminal 25 kDa fragment
(hTDP-C25, residues 219–414) led to severe locomotor defects
(Zhang et al., 2011). Analogous to human pathological data
(Arai et al., 2006; Neumann et al., 2006), hTDP-C25 was found
predominantly in the insoluble fraction, suggesting a high
propensity for aggregation. Since an elevated temperature
was linked to increased accumulation of hTDP-C25-YFP
in both soluble and insoluble fractions, Zhang et al., 2011
used RNAi to knockdown components of the protein quality
control network, finding that HSF1 was a major protective
factor in toxicity in hTDP-43 protein aggregation. HSF-1
partial loss-of-function mutations enhanced the locomotor
defects observed in hTDP-C25-YFP transgenic lines. Besides,
the insulin-like/IGF1 signaling (IIS) receptor DAF-2, which
requires HSF1 for pro-longevity effects (Morley and Morimoto,
2004), also modulates the toxicity of hTDP43. daf-2 mutants
live twice as long as WT animals (Kenyon et al., 1993), and
genetic crosses between daf-2(-) and hTDP-43 transgenic
lines improved locomotion and reduced hTDP-43-YFP
aggregation (Zhang et al., 2011). These data suggest that
molecular chaperones and protein quality control play an
important role in attenuating hTDP43 aggregation and related
behavioral deficits.
Neuronal expression of untagged wild-type and mutant
(G290A, A315T, and M337V) hTDP-43 also showed similar
locomotion defects, with some evidence of aggregate
formation in the nucleus of C. elegans neurons (assayed via
immunostaining) in all transgenic lines (Liachko et al., 2010).
Although both WT and mutant hTDP-43 lines showed reduced
locomotion on day one of the assays, this was more severe in
ALS-linkedmutant lines and deterioratedmore rapidly in hTDP-
43(mutant) lines with increasing age. hTDP-43(mutant) lines
also showed degeneration of GABAergicmotor neurons, whereas
hTDP-43WT animals did not show significant differences
compared to non-transgenic controls (Liachko et al., 2010). The
authors also show that phosphorylation at S409/410 is important
for toxicity inC. elegansmodels, as mutating the S409/410 sites to
alanine in hTDP-43(mutant) lines was able to partially rescue the
locomotion defects observed in G290A and M337V transgenic
animals (Liachko et al., 2010). As TDP-43 phosphorylated at
S409/410 is linked to pathological inclusions in both sporadic
and fALS, as well as FTLD (Inukai et al., 2008; Neumann et al.,
2009), this demonstrates that the C. elegans models generated in
these studies recapitulate aspects of TDP-43 pathology observed
in humans.
Restricting expression of wild-type and mutant (A315T)
hTDP-43 to GABAergic motor neurons of C. elegans led to
adult-onset, age-dependent paralysis and progressive motor
neuron degeneration in hTDP-43(mutant) lines (Vaccaro et al.,
2012b). This is distinct from the models described earlier,
which already showed significant locomotor defects on the
first day of adulthood (Liachko et al., 2010; Zhang et al.,
2011), suggesting that motor neuron transgenic lines are
not affected developmentally nor show general deficiencies.
Nonetheless, motor neuron-restricted transgenic lines showed
hTDP-43A315T aggregate formation in the cytoplasm and nucleus
of neurons in day 1 adults. The authors suggest that their
model, with its strong age-dependent phenotypes, can be used
for medium-throughput screens for genetic modifiers or small
molecule inhibitors of hTDP-43 toxicity (Vaccaro et al., 2012b).
Indeed, the compound TRVA242 was found to potently rescue
locomotor defects of this C. elegans model in a screen of
3,765 novel small molecule derivatives of pimozide (Bose et al.,
2019), a neuroleptic proposed to be used as a therapeutic for
ALS (Patten et al., 2017). In addition to Methylene Blue, a
compound that enhances oxidative stress responses (Stack et al.,
2014), compounds known to act specifically on endoplasmic
reticulum (ER) stress [such as salubrinal (Boyce et al., 2005) and
guanabenz (Tsaytler et al., 2011)] also protected against hTDP-
43A315T-mediated locomotor deficits in the C. elegans model
(Vaccaro et al., 2013). This result adds to growing evidence
that ER stress may be an attractive therapeutic target for ALS
(Medinas et al., 2017a).
In a study focusing on the C. elegans ortholog of TDP-43
(TDP-1, referred to here as ceTDP-43), the authors showed
that ceTDP-43 knockout was linked to sensitivity to oxidative
and osmotic stress, as well as increased lifespan at moderate
(20◦C) temperatures. Unlike effects on hTDP-43 transgenic
animals, the effects of the IIS pathway on ceTDP-1-mediated
stress responses and lifespan are less clear—two distinct DAF-2
insulin receptor mutants have opposing effects, making it more
difficult to derive a conclusive mechanistic link. Nonetheless,
ceTDP-43 does appear to be required for the stress resistance
in DAF-2 mutants as well as age-dependent proteotoxicity
(Vaccaro et al., 2012c).
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Pan-neuronal expression of wild-type and mutant human FUS
(hFUS) in C. elegans leads to cytoplasmic mislocalization,
aggregation, and locomotor defects (Murakami et al., 2012).
Murakami et al. (2012) generated a series of GFP-tagged hFUS
transgenic lines, including WT FUS, clinical mutations (R514G,
R521G, R522G, R524S, and P525L), and C-terminal truncations
(FUS513 and FUS501). The C-terminal truncations aim to
resemble human C-terminal splicing/frame-shifting truncation
mutations associated with severe ALS phenotypes (Dejesus-
Hernandez et al., 2010; Belzil et al., 2011). GFP-tagged hFUS
R522G, R524S, P525L, FUS513, and FUS501 showed clear
mislocalization of hFUS in the cytoplasm of neurons in the
head and body of C. elegans, whereas WT hFUS and R514G
or R521G mutations showed primarily nuclear localization.
Cytoplasmic mislocalization of FUS is correlated with behavioral
deficits, with only the strains showing cytoplasmic FUS also
displaying age-dependent locomotor defects. These strains
also showed a reduced lifespan compared with controls, as
well as colocalization of FUS-GFP variants with cytoplasmic
stress granule markers following acute heat stress (Murakami
et al., 2012). To test whether mutant FUS can, under stress
conditions, trigger the mislocalization of FUSWT from the
nucleus to the cytoplasm, the authors co-expressed TagRFP-
hFUSWT together with GFP-FUSP525L. After heat shock, TagRFP-
WT-hFUS remained in the nucleus whereas GFP-FUSP525L could
be observed in both the nucleus and cytoplasm (in cytoplasmic
structures resembling stress granules). The authors conclude
that mutated FUS is likely to be pathogenic through a gain-
of-function effect, rather than through titrating WT-FUS from
the nucleus. In future work, it would be interesting to assess
whether the colocalization of FUS with stress granules can be
initiated by stressors other than acute heat stress (Huelgas-
Morales et al., 2016), such as oxidative stress (Vance et al., 2013)
or in the context of aging (Cao et al., 2020). C elegans is an ideal
model system to explore the biology of stress signaling during
aging due to its short lifespan and ease of growth/maintenance
(Olsen, 2006).
In a C. elegans model expressing wild type and S57∆ mutant
hFUS in GABAergic motor neurons, hFUS transgenic lines
showed adult-onset, age-dependent locomotion deficits (Vaccaro
et al., 2012b). These age-dependent behavioral effects correlate
with motor neuron degeneration, which is more severe in
hFUSS57∆ transgenic animals compared with hFUSWT (Vaccaro
et al., 2012b). Using the same model, the neuroprotective agent
Methylene Blue was able to alleviate behavioral defects in
hFUSS57∆ animals in a dose-dependent manner, potentially by
protecting against oxidative stress (Vaccaro et al., 2012a). Given
the link between oxidative stress, aging, and proteostasis, further
investigation into how oxidative stress responses modulate FUS
pathology will be of significant interest.
Drosophila melanogaster
Research using the fly Drosophila melanogaster has made
significant contributions to our understanding of nervous
system development, function, and disease (Bellen et al., 2010;
Owald et al., 2015). Drosophila has been used as a model
organism for over 100 years: its genetic power combined with a
relatively small brain (∼250,000 neurons in adult) and complex
array of behaviors that can be rapidly assessed experimentally,
provides a powerful model animal to pursue investigations into
the mechanisms of neuronal dysfunction (Casci and Pandey,
2015). Like C. elegans, Drosophila is amenable to genetic
manipulation via RNAi (Dietzl et al., 2007) as well as tissue-
specific transgene expression via the commonly-used Gal4/UAS
(Upstream Activation Sequence) system (Brand and Perrimon,
1993). Drosophila is also cheap to grow and maintain, has a short
generation time (∼10 days), and is a more practical and ethical
system than mammalian models to perform large-scale genetic
or pharmacological screens (St Johnston, 2002; Hales et al., 2015).
Another key advantage of Drosophila models is the high degree
of genetic conservation with the human genome (∼60%; Dietzl
et al., 2007). Last, sophisticated imaging approaches have been
developed for systematic investigation of Drosophila neurons,
both in terms of neuroanatomy (Jenett et al., 2012) as well as
‘‘functional imaging’’ of neuronal activity, i.e., calcium/voltage
sensors and optogenetics (Simpson and Looger, 2018). Indeed,
current advances in mapping the synaptic connectivity of the
Drosophila nervous system are well underway, and early data
releases are showing exciting promise for neurobiology research
in this model animal (Zheng et al., 2018).
Superoxide Dismutase 1
Early fly models, like those in C. elegans, were based on
the expression of human SOD1 in Drosophila neurons. Flies
expressing wild-type hSOD1 as well as A4V and G85R mutant
forms in motor neurons showed no gross developmental or
lifespan defects but showed age-dependent progressive motor
defects in all lines when compared with a control line expressing
Drosophila SOD1 (dSOD1). Interestingly, although the hSOD1-
G85R line showed the most significant locomotor defect, this
did not correlate with a gross reduction in the number of
motor neurons in the thoracic ganglia or with the formation of
insoluble species in these neurons (Watson et al., 2008). Also,
expression of mutant or wild-type hSOD1 led to upregulation of
Hsp70 expression in surrounding glial cells—whether this glial
response is protective to motor neurons is not known (Watson
et al., 2008). Indeed the role of the heat shock response in
glial cells in ALS pathogenesis is not yet clear and is an area
of active study (Robinson et al., 2005; Liddelow et al., 2017;
San Gil et al., 2017).
Ubiquitous expression of zinc-deficient hSOD1-D83S in
Drosophila resulted in age-dependent locomotor defects but no
substantial loss of neurons or reduction in lifespan compared
with non-transgenic or hSOD1WT transgenic flies (Bahadorani
et al., 2013). Tissue-specific expression of hSOD1-D83S in all
neurons or in glia had the most potent effect on locomotion,
with motor neuron-restricted expression having a moderate
impact. However, no defects were observed upon expression
in muscle, and no reduction in lifespan was seen compared
to hSOD1WT transgenic animals. These defects correlated with
increased sensitivity to the oxidative stressor paraquat and
dysfunction of the mitochondrial respiratory chain (Bahadorani
et al., 2013). These results agree with the previously mentioned
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purified protein and cell culture data, suggesting that structural
destabilization of SOD1 is a crucial factor in the formation of
toxic species and aggregates in cells.
dSOD1 is highly similar to hSOD1, being identical
at 104/153 residues. Şahin et al. (2017) engineered the
ALS-associated mutations G37R, H48R, H71Y, and G85R
into the endogenous locus of dSOD1 to generate mutant ‘‘knock-
in’’ lines. These lines showed varying effects: compared with
dSOD1(WTLoxP) controls, homozygous dSOD1 H71Y showed
reduced lifespan, reduced fertility, and increased sensitivity to
oxidative stress. dSOD1-G85R and dSOD1 H48R lines were
developmentally lethal as homozygotes, but dSOD1-G85R
heterozygotes showed normal lifespan and oxidative stress
responses. dSOD1-G37R animals were phenotypically
normal compared to controls. In larvae, dSOD1-G85R and
dSOD1-H71Y homozygotes showed severe climbing defects
that were suppressed in heterozygotes of each transgene.
These were not correlated with a gross reduction in motor
neuron number. However, dSOD1-G85R and dSOD1-H71Y
animals showed reduced dSOD1 protein levels and enzymatic
activity (Şahin et al., 2017). These models, which express
ALS-linked mutant SOD1 from the endogenous dSOD1 locus,
will be useful tools for future analysis or high-throughput
genetic/pharmacological screens.
Transactive Response DNA-Binding Protein 43
Expression of a repeated form of amino acids 342–366 (12xQ/N)
of TDP-43 in the Drosophila eye leads to the formation of
insoluble aggregates that were by themselves not strongly
neurotoxic (Cragnaz et al., 2014). Over-expression of the
Drosophila ortholog of TDP-43 (TBPH, referred to here as
dTDP-43) in the eyes leads to significant levels of tissue
degeneration. This toxicity was completely reverted by the
co-expression of EGFP-tagged 12xQ/N. The authors proposed
that dTDP-43 may be sequestered in aggregates formed by
EGFP-12xQ/N, thereby titrating excess dTDP-43 (Cragnaz et al.,
2014). In this case, the formation of aggregates is protective.
When EGFP-12xQ/N is expressed in fly neurons, it results in
an age-associated locomotor defect and a shortened lifespan
(Cragnaz et al., 2015). In the neuronal model, the authors
suggest that the locomotor defect is correlated with reduced
levels of endogenous dTDP-43 (protein and mRNA levels),
due to dTDP-43 being sequestered in EGFP-12xQ/N aggregates
(Cragnaz et al., 2015). This can be compensated in younger
animals by increased protein production, but in older animals,
the lower capacity for protein synthesis (Liang et al., 2014;
Anisimova et al., 2018) may lead to a loss-of-function effect due
to reduced dTDP-43 levels.
Over-expression models where wild-type or human
hTDP-43 is expressed in fly neurons have also provided
interesting insights into TDP-43-linked ALS/FTLD pathology.
Miguel et al. (2011) generated Drosophila models expressing
FLAG-tagged hTDP-43WT, hTDP-43 with a defective NLS
(hTDP-43∆NLS—predominantly cytoplasmic localization) or
hTDP-43 with a defective NES (hTDP-43∆NES—restricted
to nuclear localization). Neuron-specific expression of these
transgenes was larval lethal, so an inducible system was used to
bypass developmental effects (Miguel et al., 2011). Compared
with controls, all inducible transgenic flies showed a reduced
lifespan. Biochemical analysis (immunoblot) demonstrated
that hTDP-43, hTDP-43∆NES, and hTDP-43∆NLS proteins
could be detected in monomeric form or as high molecular
weight (HMW, potentially aggregated) species, although hTDP-
43∆NES and hTDP-43∆NLS expression showed more HMW
species compared with hTDP-43WT. When probed with an
antibody against phospho-TDP-43(S409/410), hTDP-43∆NES
HMW species, but not those of hTDP-43WT or hTDP-43∆NLS,
were strongly labeled by the pTDP-43 antibody. Interestingly,
immunostaining did not reveal the presence of inclusions
formed by the expression of any of these transgenes, suggesting
that toxicity (reduced survival) does not require the formation
of inclusions. This study also demonstrated cell-type-specific
toxicity resulting from the expression of hTDP-43 transgenes:
in adult neurons, both nuclear and cytoplasmic accumulations
of TDP-43 result in toxicity, whereas in muscle and glial cells,
only the accumulation of cytoplasmic species of TDP-43 was
toxic (Miguel et al., 2011). This could be due to differences
in proteostasis mechanisms in different tissues, such as the
capacity for protein production, differences in post-translational
modification, or sequestration of aggregated/oligomeric forms
(Vilchez et al., 2014).
TDP-43 autoregulates its own levels through binding to
a TDP-43 binding region (TDPBR) in its 3′ UTR (Ayala
et al., 2011). Expression of hTDP-43 containing the TDPBR
in Drosophila retinal cells led to significantly reduced protein
and mRNA levels for hTDP-43 (Pons et al., 2017), similar to
observations in cultured cells and mammalian models (Ayala
et al., 2011; Polymenidou et al., 2011). This hTDP43_TDPBR
transgenic line can then be used to perform genetic crosses with
Drosophilamutant strains to identify other factors that modulate
hTDP-43 levels through the TDPBR. Pons et al. (2017) used this
method to identify Drosophila splicing factors that modulated
hTDP-43 levels, and in a follow-up study, identified the protein
CG42724 [and its human orthologue Transcription elongation
regulator 1 (TCERG1)] as a modulator of hTDP-43 protein levels
(Pons et al., 2018).
TDP-43 has been shown to associate with human Hsc70 in
cultured mammalian cells (Freibaum et al., 2010). In Drosophila,
one of the Hsc70 proteins (Hsc70–4) is highly expressed
in neurons and functions in synaptic vesicle exo- and
endocytosis (Bronk et al., 2001; Chang et al., 2002). Coyne
et al. (2017) showed that Drosophila Hsc70–4 associates
with transgenic hTDP-43 in fly motor neurons. As a result,
over-expression of hTDP-43 in motor neurons sequesters
Hsc70–4, leading to reduced synaptic expression. This ultimately
inhibits synaptic vesicle endocytosis and results in defects
in synaptic transmission (Coyne et al., 2017). Interestingly,
expression of ALS-linked mutant forms of hTDP-43 leads to
locomotor defects that can be rescued by over-expression of
wild-type Hsc70–4, but not mutant forms that are defective
in chaperone (Hsc70–4D10N) or microautophagy functions
(Hsc70–43KA). This suggests that hTDP-43 compromises
both chaperone and microautophagy activities of Hsc70–4
(Coyne et al., 2017).
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Drosophila models have also been useful in investigating the
pathological roles of ALS-associated protein FUS. Transgenic
Drosophila lines were generated expressing hFUSWT and two
disease-related variants hFUSP525L and hFUSR495X (Jäckel et al.,
2015). Expression in motor neurons resulted in viability defects
and locomotor defects in hFUSWT and hFUSP525L, but not
in hFUSR495X-expressing flies. Immunostaining showed that
hFUSWT localized to the nucleus, whereas hFUSP525L showed an
additional cytoplasmic staining, and hFUSR495X was observed at
relatively equal levels in the nucleus and cytoplasm. The lack
of phenotype observed in hFUSR495X flies is surprising because
the R495X mutation is linked to a highly aggressive form of
ALS (Chiò et al., 2009b). The pathological role of hFUSR495X in
this Drosophila model could not be associated with its partial
cytoplasmic mislocalization, which is thought to be a critical
disease mechanism (Kim and Taylor, 2017), suggesting that
disease-modifying factors are missing in this model.
FUS expression can autoregulate its levels in cultured cells
(Zhou et al., 2013; Dini Modigliani et al., 2014). Similarly, in
Drosophila, over-expression of hFUS in fly motor neurons
leads to decreased levels of the endogenous Caz protein
(the Drosophila ortholog of FUS—dFUS; Machamer et al.,
2014; Jäckel et al., 2015). These changes are correlated with
alterations in neuromuscular junction structure and defects in
synaptic transmission. In contrast, Caz/dFUS null alleles show
enhanced synaptic transmission as demonstrated by increased
excitatory junction potential (EJP) amplitude (Machamer
et al., 2014). Therefore, although hFUS over-expression
(both WT and mutant) leads to lower levels of Caz/dFUS,
this is likely not the mechanism by which hFUS triggers
synaptic dysfunction.
Both TDP-43 and FUS are components of the biomolecular
condensate compartment known as stress granules through
interactions in their respective LCDs (Harrison and Shorter,
2017). A Drosophila study performed a systematic domain
deletion screen of FUS, to identify toxicity-mediating domains
(Bogaert et al., 2018). Deletion of the N-terminal QGSY
prion-like LCD partially rescued toxicity. The C-terminal RGG-2
region was also essential for toxicity, and the two domains appear
to act synergistically. Interestingly, the prion-like QGSY domain
is not found in Caz/dFUS, which may differentiate between
toxicity caused by human and fly orthologs (Bogaert et al.,
2018). The nuclear-import receptor Kap-β2 (Karyopherin-β2)
inhibits phase-transition and fibrillization of FUS in vitro. Also,
transgenic expression of Kap-β2 and could rescue the shortened
lifespan of Drosophila expressing hFUSR521H, thereby mitigating
hFUS induced motor-neuron toxicity in vivo (Guo et al., 2018).
For a visual summary of the advantages of using invertebrate
models, see Figure 4.
Mouse Models of ALS
Mouse models of ALS have been a key system by which our
understanding of the underlying molecular pathology of ALS
develops. In this section, we will describe the current mouse
models used to examine both protein homeostasis and prion-like
propagation in ALS.
Superoxide Dismutase-1
Since the seminal discovery identifying the association of
SOD1 mutations with fALS (Rosen et al., 1993), several
SOD1 transgenic mouse models have been generated. Despite
the discovery of several other genes and a relatively small
percentage of patients exhibiting SOD1 mutations, SOD1 mouse
models are still the most extensively used model to investigate
the pathogenesis and treatment of ALS. The first transgenic
SOD1 mouse model expressed hSOD1 with the G93A mutation
(denoted SOD1-G93A; Gurney et al., 1994). Transgenic
SOD1-G93A mice exhibit phenotypic symptoms at 3–4 months
of age and subsequently develop ubiquitinated SOD1 deposits,
similar to those found in fALS post-mortem tissue (Bruijn
et al., 1997). Years after its initial generation, this model
provided the first in vivo clues indicating that SOD1 acts in a
prion-like fashion. Deng et al. (2006) observed that crossing
human wild-type SOD1 mice with SOD1-G93A transgenic mice
accelerated ALS-like phenotypes. Furthermore, soluble human
wild-type SOD1 was converted to an aggregated and detergent-
insoluble conformation. Also, spinal cord homogenates from
SOD1-G93A mice were used to seed recombinant purified
SOD1 to form amyloid fibrils (Chia et al., 2010).
The studies described above hinted at the ability of SOD1 to
propagate in a prion-like manner but lacked animal-to-
animal transmission. Utilizing experimental paradigms from
the prion field, Ayers et al. (2014) were the first to provide
bona fide in vivo evidence of SOD1 prion-like propagation.
Heterozygous mice expressing SOD1-G85Rmutant C-terminally
tagged with a yellow fluorescent protein (SOD1-G85R:YFP) do
not develop an ALS phenotype (Wang et al., 2009b). However,
when spinal cord homogenates from paralyzed SOD1-G93A
mice were injected into the spinal cord of SOD1-G85R:YFP
mice at PN0 (postnatal day 0), some (∼50%) of these mice
subsequently developed ALS-like phenotypes, including paralysis
as early as 6 months of age, as well as reduced life-span
(Ayers et al., 2014). However, when spinal cord homogenates
from SOD1-G93A inoculated SOD1-G85R:YFP mice were
subsequently re-passaged into newborn SOD1-G85R:YFP mice,
all of these mice developed ALS symptoms, and at an earlier
time-point. Furthermore, SOD1-G93A recipient mice exhibited
SOD1-G85R:YFP protein aggregates in the spinal cord as
well as in the brain stem, suggesting prion-like spread distal
to the site of injection. Also, second passage inoculation of
naïve adult SOD1-G85R:YFP mice resulted in paralysis of the
ipsilateral hind-limb of the injection site within 1 month,
followed by contralateral leg paralysis after 2 months and
reaching end-stage paralysis within 3 months post-injection.
Furthermore, post-mortem analysis of mice at several time points
post-injection showed inclusion pathology in both neurons and
astrocytes in the dorsal root ganglion, cervical spinal cord,
and brain stem (Ayers et al., 2016), suggesting focal spreading
throughout the CNS, a classic hallmark of pathological prion
propagation. It is important to note that YFP-tagged SOD1 is
not required as a template for seeding, as other work has
shown untagged mutant SOD1 expressed in mice can be
efficiently seeded by injection of preformed SOD1 aggregates
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(Bergh et al., 2015; Lang et al., 2015; Bidhendi et al., 2016;
Bidhendi et al., 2018).
Whilst it is unclear how SOD1 spreads throughout the CNS,
in vitro studies highlight the important role of exosomes in the
extracellular transmission, yet in vivo experiments supporting
such transmissibility have yet to be explored or reported. These
studies may be of use to aid in the design of anti-propagation
therapeutic avenues. In line with this, in vitro work has shown
small molecules that interact with or near the Trp32 residue
of SOD1 can reduce its aggregation propensity. Furthermore,
Trp to Ser substitutions at the 32 position residue can suppress
intra- and intercellular propagation (Grad et al., 2011, 2014),
suggesting its involvement in SOD1 prion-like propagation.
However, some research showed that recombinant SOD1 with
a Trp32Ser (W32S) substitution produced a similar disease
frequency and earlier disease onset compared toWT SOD1 when
seeded in G85R-SOD1:YFP mice (Crown et al., 2020), suggesting
that fibrillation through other amyloidogenic regions within
SOD1 may also confer disease. The Trp32 residue is conserved
to human SOD1 in beta-sheet 3 and not present within mice.
To date, there are no reports of a transgenic SOD1 mouse
model expressing modifications to the Trp32 residue, however,
such a model may lead to further understanding its role in
SOD1 aggregation and prion-like propagation.
Various prion isolates can develop a heterogeneous
pathology giving rise to prion strains that are determined
by variability within their tertiary conformation. Similarly, fALS
SOD1 mutations display a heterogeneous disease pathology,
which has been proposed in part due to their tertiary structure
and propensity to aggregate (Prudencio et al., 2009). Using
binary epitope mapping with several anti-peptide antibodies
covering the entire SOD1 protein, Bergh et al. (2015) used
insoluble material obtained from wild-type and mutant (G85R,
D90A, and G93A) SOD1 mice to show evidence of two distinct
strains (referred to as A and B by the authors). Strain A
aggregates were observed in all SOD1 mutant mice investigated,
while strain B was only observed in D90A mice. In vitro,
biochemical/physical examination of strain A and B showed
variation in their aggregation structure, kinetics, and fragility,
with strain B showing increased aggregation kinetics and fragility
(Lang et al., 2015). Furthermore, injection of strain A and B in the
lumbar spinal cord of adult SOD1G85R mice showed both strains
were capable of seeding and transmissibility, with the rostral
spreading of aggregates, subsequently causing end-stage death
∼100 days following injection (Bidhendi et al., 2016). Later,
injection of spinal cord homogenate from a patient carrying
the SOD1-G127X mutation into transgenic mice carrying the
same mutation showed propagation of strain A into the mice,
suggesting that this aggregate conformer may exist in humans
(Bidhendi et al., 2018).
Whilst the evidence and modeling are still in the early days,
these data collectively support the ability of SOD1 to undergo
prion-like propagation. Future experiments using SOD1 mice
with various amyloidogenic regions within SOD1 deleted and/or
the use of synthetic peptide samples composed of a single
amyloidogenic segment of SOD1 would be useful to reveal the
mechanistic details of this pathology.
Transactive Response DNA-Binding Protein 43
TDP-43 has been extensively implicated in ALS, in addition to
FTLD, due to the high majority of both fALS and sALS patients
exhibiting insoluble and ubiquitinated TDP-43 cytoplasmic
inclusions withinmotor neurons and glia (Neumann et al., 2006).
Several TDP-43 transgenic mouse models have been generated
which show motor deficits, neuronal loss, and mislocalized
TDP-43 inclusions (Lee et al., 2012). However, overexpression of
WT TDP-43 can cause similar pathology, making it difficult to
distinguish the pathological effects of various mutations without
adequate control over transgene expression. To overcome these
issues, several groups have produced sophisticated knock-in
models to control for transgene overexpression. These models
include introducing Hemi- and homologous TDP-43 transgene
mutations at G298S, Q331, and M337V (Fratta et al., 2018;
White et al., 2018; Ebstein et al., 2019; Gordon et al., 2019).
Interestingly, these mice homologous for these transgenes
show motor deficits and in some cases, motor neuron loss
in the absence of mislocalized TDP-43, suggesting TDP-43
mislocalization may not be the cause of motor neuron toxicity
in ALS (Fratta et al., 2018; White et al., 2018; Ebstein et al., 2019;
Gordon et al., 2019).
Observations from ALS and FTLD post-mortem tissue
suggests that TDP-43 also exhibits prion-like propagation and
spreading throughout neuroanatomical tracts. Until recently
there has been a lack of in vivo investigation into the prion-like
propagation of TDP-43 using animal models. Employing a
cell-based screening system, Porta et al. (2018) were able
to apply sarkosyl-insoluble frontal cortex homogenates from
FTLD-TDP subjects to identify those with seeding capacity.
Subsequently, samples that showed in vitro seeding capacity
were injected into the brains (neocortex, hippocampus, and
thalamus) of doxycycline-regulatable transgenic mice expressing
a human TDP-43∆NLS in forebrain neurons (under a CAMKIIa
promoter). Recipient mice displayed pTDP-43 inclusions within
the ipsilateral injection site within 1-month post-injection, with
relatively few inclusions observed on the contralateral side.
Furthermore, spatiotemporal immunohistochemical analysis
of mice injected with TDP-43 seeding material showed a
transneuronal-like spreading pattern of TDP-43 pathology in the
1–9 months following injection. Unsurprisingly, a large majority
of TDP-43 aggregates were observed within forebrain neuronal
cells where the CAMKIIa promoter controls the expression
of TDP-43∆NLS. However, TDP-43 aggregates were also found
within the subcortical regions including the nucleus accumbens
and caudate-putamen, suggesting regional spreading.
Furthermore, similar to ALS/FTLD post-mortem
samples, TDP-43 aggregates were also sparsely observed in
oligodendrocytes and astrocytes, suggesting local cell-to-
cell transmission that is not dependent on the subcellular
mislocalization of TDP-43. Further supporting this, seeding was
also observed in wild-type mice injected with FTLD-derived
material, however, the capacity was less than NLS-mice.
Furthermore, injection of FTLD material in mice overexpressing
cytoplasmic TDP-43 C-terminal fragments did not show
TDP-43 pathology, indicating a role for the N-terminal sequence
in TDP-43 in prion-like seeding. While this study provides
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initial in vivo evidence for the prion-like characteristics of
TDP-43, further research is required to identify the specific
regions of TDP-43 that are important for seeding. As mentioned
previously, full-length TDP-43 and its CTFs have multiple
amyloidogenic regions (Guenther et al., 2018a,b). Assessing the
contribution of each of these segments would be essential to
determine the sequence region by which TDP-43 aggregates
propagate. This information would allow for the design of
therapies that may block templating or cell-to-cell transmission
of TDP-43 prion-like particles.
Fused in Sarcoma
FUS knockout mouse models do not show evidence of motor
impairments or ALS associated histopathology, suggesting that
a FUS loss-of-function mechanism is not responsible for ALS
pathology. However, several groups have developed human
wild-type FUS (hFUS) overexpression mouse models under
various promoters. Mitchell et al. (2013) were the first to
produce a FUS overexpression model, whereby hFUS levels
were ∼1.9 times higher than wild-type mice. These mice
develop paralysis at 10–12 weeks of age (Mitchell et al., 2013).
Furthermore, overexpression of hFUS resulted in the cytoplasmic
mislocalization of the ectopic protein in the brain and spinal
cord. However, cell loss was only observed in the spinal
cord, indicating that lower motor neurons may be prone to
FUS overexpression.
FUS mutations are inherited in an autosomal dominant
fashion, with FUS-R521C mutations commonly observed in
FUS-associated fALS patients. Qiu et al. (2014) developed a
transgenic FUS-R521C mouse model that exhibited aggressive
motor function deficits and reduced life span. These transgenic
mice showed alterations in the transcription and splicing of the
growth factor BDNF, which is regulated by FUS. Spinal cord
homogenates from FUS-R521C mice showed a high propensity
to form complexes with FUS-WT, consistent with experiments
in HEK293T cells co-expressing mutant- and FUS-WT. Together
with the autosomal dominant inheritance of FUS mutations,
these data support a gain of function property of mutant
FUS, which may sequester FUS-WT from carrying out its
physiological role.
Recently, Zhang et al. (2020) employed two-photon imaging
in combination with a knock-in mouse model of FUS-R521C.
They showed that mutant FUS was incorporated and potentiated
stress granule formation following arsenite challenge. Expression
of mutant FUS also caused the cytoplasmic mislocalization of
mutant FUS and upregulation of ubiquitin, which appeared to be
also co-localized. Also, neurons that showed an inability to clear
or disassemble stress granules died within days following arsenite
challenge, highlighting the role of stress granule formation in the
pathogenesis of ALS.
To distinguish the pathological role of FUS aggregates without
the confounding effects on RNA metabolism, Shelkovnikova
et al., developed a transgenic mouse expressing a truncated
human FUS protein (residues 1–359), which lacked the RNA
recognition motif and NLS but still retained an N-terminal
QGSY prion-like domain (Shelkovnikova et al., 2013). These
mice developed paralysis, exhibited motor neuron loss, and
reduced life-span. Furthermore, the truncated FUS protein
formed aggregates, and subsequent FUS inclusions containing
endogenous murine FUS were observed in the motor cortex and
lowermotor neurons. Collectively this study suggests thatmutant
FUS may exhibit a seeding capacity, which is capable of causing
motor neuron degeneration in the absence of its role in RNA
processing. For a visual summary of the key features of murine
models, see Figure 5.
THERAPEUTIC STRATEGIES TO TARGET
PROTEOSTATIC IMPAIRMENT AND
PRION-LIKE PROPAGATION IN ALS
Currently, only two therapies exist for the treatment of ALS in
humans. The first, riluzole, interrupts glutaminergic signaling
(Bryson et al., 1996) potentially through preventing glutamate
release (Kretschmer et al., 1998). Riluzole treatment led to
increased motor function and survival in an initial clinical
trial (Bensimon et al., 1994; Lacomblez et al., 1996); however,
improvements in survival were not observed in a follow-up
clinical study. Also, riluzole only extends lifespan by 3–6 months,
and only in patients with moderate impairment (Bensimon
et al., 1994; Lacomblez et al., 1996). The second compound,
edaravone, is a free-radical scavenger (Yoshino and Kimura,
2006), which is primarily sold to promote recovery from stroke in
Japan due to its ability to prevent edema, neuronal damage, and
neurological defects in rats (Edaravone Acute Infarction Study
Group, 2003). Edaravone is offered as a therapeutic to treat ALS
in Japan, South Korea, the US, and Canada, but is not being
used elsewhere (Yoshino, 2019). Clinical trials using edaravone
did not demonstrate a benefit for the majority of patients, with a
follow-up clinical study suggesting that edaravone only benefits
patients with mild impairment [Yoshino and Kimura, 2006; Abe
et al., 2014; Writing Group; Edaravone (MCI-186) ALS 19 Study
Group, 2017]. The above highlights how the only two drugs
currently offered to treat ALS symptoms are limited in scope, and
there is a dire need for new therapies that potentially target one
or more ALS-associated aggregating proteins.
In silico and In vitro High-Throughput
Identification of Potential Therapeutics
With improved computing power and rapidly-evolving methods
to better examine protein structure, computational modeling
is being utilized as a means for drug discovery. Due to
the lack of need for biological material, and bioinformatic
nature, computational screening of drugs can be carried out
rapidly and efficiently. Additionally, high-throughput screens
using in vitro models that recapitulate some aspects of ALS
pathology can be utilized to rapidly screen potential drugs to
determine their biological activity and therapeutic potential. A
recent review of high-throughput screens investigating drugs
that alter ALS pathology was published by McGown and
Stopford (2018). This review describes studies that investigated
reducing SOD1 transcription, protein aggregation, and oxidative
stress as a therapeutic strategy, as well as the potential of
anti-glutamatergic and cytoprotective drugs for the treatment
of ALS. Studies focusing solely on drug candidates that modify
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FIGURE 5 | Murine models of protein aggregation and prion-like propagation. Murine models form the crux of our pathobiological understanding of the effects of
protein aggregation and prion-like propagation in mammals. This is due to their genetic similarity with humans, which translates into similar physiology, similar
disease susceptibility, and similar neuroanatomy. The input of disease-associated genes into mice often results in similar clinicopathological features including
behavioral deficits, protein aggregation, and loss of neurons in specific tissues. Prion-like propagation can be assayed through the injection of seed protein
aggregates into specific locations, and the passage of extracted prion-like seeds can be used to define strains. Finally, these models are the gateway to the clinic
and are mostly used for the testing of drugs and therapies that are aimed at alleviating human disease.
protein aggregation that was described briefly in the review, and
studies published since are discussed below.
Superoxide Dismutase-1
A computational screen found 16 novel compounds that bound
mutant SOD1-A4V and prevented its aggregation in vitro
(Ray et al., 2005), however, these compounds did not exert
this effect in the presence of blood plasma (Nowak et al.,
2010). Subsequent computational work identified 6 different
novel compounds that bound SOD1 in the presence of
plasma (Nowak et al., 2010), but these are yet to be
tested in vitro or in vivo. Using in vitro aggregation assays
of SOD1-G37R protein, Anzai et al. (2016) tested 640
FDA-approved drugs and identified seven hit compounds, with
six able to completely suppress SOD1 aggregation (measured by
turbidity). Three of these were statins (simvastatin, lovastatin,
and mevastatin), another three were vitamin D derivatives
(alfacalcidol, calcidiol, and calcitriol), and the final drug
was miltefosine, an antimicrobial. A computational screen of
∼4,400 compounds revealed that quercitrin, quercetin-3-β-D-
glucoside, and epigallocatechin gallate (EGCG) bind directly
to SOD1-A4V and inhibit ROS-induced SOD1 aggregation (Ip
et al., 2017), but only the latter has been tested in vitro and
in vivo. EGCG administered in SOD1-G93A mice improved
disease compared to controls, delaying means symptom onset
(128 days vs. 115 days), locomotor deficits measured by rotarod
test (140 days vs. 120 days), and mortality (mean survival
time 143 days vs. 123 days), however the mechanism was not
described (Koh et al., 2006), and this drug has not progressed to
clinical trials.
Using high-throughput in vitro screening using an inducible
SOD1-G37R PC12 cell line, Broom et al. (2006) screened
116,680 compounds from various libraries and found
67 hit compounds. However, most compounds exhibited
cytotoxicity or failed to have their effect replicated, and
only 2 hits (no description available) are being investigated
further. Rather than using SOD1 aggregation as a readout,
Wright et al. (2012) instead investigated SOD1 transcription
using PC12 cells transfected with SOD1-GFP to screen
30,000 compounds, with the most potent inhibitor of
SOD1 transcription being N-[4-[4-(4-methyl benzoyl)-
1-piperazinyl]phenyl]-2-thiophenecarboxamide. In vivo
experiments using a SOD1-G93A mouse model showed
that the drug was well tolerated, with toxicity estimated to
be 75 mg/kg. These mice also showed a significant decrease
in SOD1 protein levels, but aggregation was not described
(Wright et al., 2012).
Finally, using iPSC-derived motor neurons from fALS
patients, Imamura et al. (2017) screened 1,416 compounds and
determined the Src/c-Abl tyrosine kinase inhibitor bosutinib
improved iPSC-derived motor neuron survival, potentially
through clearance of SOD1 aggregates by up-regulation of
autophagy pathways. Intraperitoneal injection of bosutinib
(5 mg/kg) into transgenic SOD1-G93A mice daily starting at
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8 weeks of age for 5 weeks, reduced misfolded SOD1 and
motor neuron degeneration in spinal cords, as well as delaying
disease onset by 10.8 days and extending survival by 7.8 days
(Imamura et al., 2017).
Transactive Response DNA-Binding Protein 43
Boyd et al. (2014) generated a doxycycline-inducible TDP-
43-GFP expressing PC-12 cell line to screen ∼75,000 small
molecules to identify those that reduce sodium arsenite-
induced TDP-43 aggregates as measured by microscopy.
One compound, termed LDN-0130436, reduced TDP-43
aggregation in a concentration-dependent manner and
was confirmed by immunoblotting. LDN-0130436 restored
behavioral defects and protected against TDP-43-induced cell
loss in C. elegans expressing mutant TDP-43A315T, however,
effects on protein aggregation in this model were not reported
(Boyd et al., 2014).
Using a luciferase-based fluorescence assay to measure
TDP-43 inclusions in the murine Neuro-2a neuroblastoma cell
line, Oberstadt et al. (2018) screened the LOPAC1280 library
(Sigma–Aldrich) and found 16 active compounds that reduced
TDP-43 dimerization by 30–82%. In an initial screen,
riluzole, one of the two therapies offered to ALS patients,
reduced N-terminal TDP-43 interactions by 82%, whilst
chelerythrine and auranofin reduced interactions by 64%
and 63%, respectively. During validation, 25 µM auranofin
significantly reduced 98% of TDP-43 interactions, whilst 25
µM chelerythrine reduced 90% of TDP-43 interactions but
exhibited a toxic effect at higher concentrations (Oberstadt
et al., 2018). Fang et al. (2019) screened 3,350 compounds in
HEK293 cells transfected with TDP-43 and 5,910 compounds in
neural progenitor cells to identify drugs that affect stress granule
formation. In this study, Anisomycin, mitoxantrone, and
GSK2656157 significantly reduced stress granule formation, and
interestingly mitoxantrone inhibited TDP-43∆NLS colocalization
with stress granules (Fang et al., 2019).
Using patient-derived iPSCs differentiated into spinal
motor neurons, Egawa et al. (2012) investigated the impact
of four compounds on arsenite-induced TDP-43 inclusion
formation and cell death. Only anacardic acid reduced TDP-43
mRNA expression, inclusion formation, and prevented cell
death. Additionally, bosutinib (mentioned above for SOD1)
demonstrated a similar reduction in TDP-43 inclusions
in iPSC-derived motor neurons. Another study utilized a
high-throughput image analysis method in iPSC-derived
motor neurons from sALS patients to screen 1,757 bioactive
compounds for the reduction of TDP-43 aggregation and
expression levels (Burkhardt et al., 2013). This screen identified
38 hits that reduced TDP-43 aggregation, but not TDP-43
expression, and subsequent validation characterized four
classes of compounds: cyclin-dependent, and c-Jun N-terminal
kinase inhibitors, triptolide, and cardiac glycosides. Another
study using iPSC-derived motor neurons from fALS patients
expressing TDP-43 mutations screened 1,232 drugs using a
high-throughput imaging system and identified the dopamine
D2 receptor antagonist ropinirole as a potential therapeutic
(Fujimori et al., 2018). Ropinirole prevented neurite regression,
stress granule formation, TDP-43 aggregation, and prevented
cell death of fALS-derived iPSCs.
Patten et al. (2017) screened 3,850 compounds in a transgenic
C. elegans model expressing mutant TDP-43A315T and identified
several neuroleptics, which rescued paralysis. Further screening
in a transgenic zebrafish model expressing mutant TDP-43G348C,
led to the identification of pimozide as a potential therapeutic,
which rescued paralysis, as well as motor neuron axon branching
and neuro-muscular junction structures. The authors also
describe that pimozide is already FDA-approved and the use of
pimozide (1 mg daily) in a randomized double-blind clinical trial
in Poland, led to a reduction in ALS severity (Szczudlik et al.,
1998), but this is yet to be investigated elsewhere.
In a transgenic Drosophila model of ALS, in which motor
neurons express mutant TDP-43D169G, TDP-43G298S, TDP-
43A315T, or TDP-43N345K, resulting in complete mortality,
Joardar et al. (2015) screened 1,200 FDA-approved drugs to
determine if any improve survival. This screen identified several
antidiabetic drugs such as thiazolidinediones, sulfonylureas,
and biguanides, with the most potent effect exhibited by
the thiazolidinedione pioglitazone. Pioglitazone prevented
locomotor deficits and glial death, but could not prevent the
death of motor neurons, and was ineffective in preventing
disease pathology in a transgenic SOD1-G85R model. This
finding contradicts two studies which have shown the benefit
of pioglitazone to rescue locomotor deficits, prevent motor
neuron death, and improve survival in transgenic SOD1-G93A
mice, however, there was no reduction in SOD1 expression,
and SOD1 aggregation was not characterized (Kiaei et al., 2005;
Schütz et al., 2005).
Using C. elegans expressing mutant TDP-43-A315T, Bose
et al. (2019) screened a library containing 3,765 novel molecules
and identified 27 hit compounds. Validation in a toxic
gain-of-function TDP-43-G348C zebrafish model identified
four of these hits which improved locomotion. One compound,
TRVA242 was identified as the most effective compound and
rescued locomotion, improved motor neuron survival, and
rescued neuromuscular junction deficits in the aforementioned
C. elegans and zebrafish model, as well as in SOD1 and
C9ORF72 zebrafish models of ALS, and in SOD1-G37R mice.
Fused in Sarcoma
High-throughput screening to investigate therapies targeting
FUS in ALS using iPSC-derived motor neurons have been
performed. A GFP-tagged FUSP525L expressing iPSC cell line
treated with sodium arsenite was used to screen ∼1,000 small
molecules to investigate stress granule formation via imaging
(Marrone et al., 2018). This screen identified 69 compounds,
and further assessment validated 13 molecules targeting
the PI3K/AKT/mTOR pathway, with the mTOR inhibitor
rapamycin reducing stress granule formation and promoting
survival of motor neurons generated from the iPSCs.
Whilst the effect of rapamycin on protein aggregation was
not characterized, rapamycin did upregulate autophagy, a
mechanism important in the clearance of protein aggregates
(Ramesh and Pandey, 2017). As mentioned above, the dopamine
receptor antagonist ropinirole prevented ALS pathology in
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iPSC-derived motor neurons from fALS patients with TDP-43
(M337V or Q343R) mutations, and similarly, ropinirole
prevented neurite regression, stress granule formation, FUS
aggregation, and prevented cell death in iPSC-derived motor
neurons from fALS patients with FUS (H517D) mutations
(Fujimori et al., 2018).
Currently, there are no high-throughput studies in vivo
focusing solely on FUS. However, as mentioned above the C.
elegans, D. melanogaster and zebrafish models of FUS represent
ideal models to investigate potential drugs, with Vaccaro et al.
(2012a) demonstrating methylene blue prevented oxidative
stress and improved locomotor defects in both a C. elegans
and zebrafish model. Additionally, Joardar et al. (2015) did
demonstrate that pioglitazone rescues locomotor function in
transgenic FUSP525L Drosophila, but does not impact survival.
Diacetylbis(N(4)-
Methylthiosemicarbazonato)-CuII
(CuATSM)
Superoxide Dismutase-1
Numerous in vitro models exist to explore the role of
SOD1 aggregation in ALS pathogenesis. In NSC-34 cells,
CuATSM decreased aggregation and increased survival in
cells transiently transfected with GFP-tagged mutant A4V,
C6G, E100G, G37R, G93A, and V148G SOD1, but not those
transfected with H46R, G85R, or G127X (Farrawell et al., 2019).
Importantly, the mutants that were not responsive to CuATSM
treatment reduce or ablate the ability of SOD1 to bind copper
(Carrì et al., 1994). This data suggests that the activity of
CuATSM in this model is to facilitate the delivery of copper
to SOD1 and thereby limit the pool of immature copper-free
SOD1 that is more prone to aggregate (Tokuda et al., 2018).
Dermal application of CuATSM improved survival in a
SOD1-G93A mouse model, with CuATSM-treated mice living a
median 155 days, compared with vehicle-treated controls with
a median lifespan of 133 days (Williams et al., 2016). Oral
administration of CuATSM delayed neurological damage and
improved latency to fall using a rotarod test, with CuATSM
mice displaying these symptoms at 113 days compared with
100 days in vehicle-treated mice. CuATSM treated mice also
demonstrated an improved mean survival time of 143 days
compared with 129 days in vehicle-treated mice (Hilton
et al., 2017). Conversely, CuATSM-treated mice demonstrated
significantly increased relative abundance of mutant SOD1-
G93A, SOD1 activity, and copper in spinal cords compared with
vehicle-treated mice. This increase can be attributed to CuATSM
facilitating increased copper delivery to SOD1 via CCS, which
can improve copper-dependent SOD1 activity, an effect that
protects motor neurons and improves disease outcomes (Soon
et al., 2011; Roberts et al., 2014; Hilton et al., 2017). This is
supported by evidence that ligand-free ATSM does not exert
protective effects compared to CuATSM (Vieira et al., 2017).
Similar to the SOD1-G93A mouse model, CuATSM also
improves locomotor function (rotarod test) and median survival
time (212–248 days depending on dose) in SOD1-G37R mice
compared to vehicle control (median survival time 196 days).
Administration of riluzole in conjunction with CuATSM did
not exhibit any additive effect (McAllum et al., 2013). In a
more severe SOD1-G93A mouse model, where mice co-express
human CCS, SOD1-G93AxhCCS mice exhibit a mean survival
time of 36 days, compared to 226 days in SOD1-G93A mice (Son
et al., 2007). Administration of CuATSM in SOD1-G93AxhCCS
mice daily from day 5 increased lifespan to >1 year, whereas
suspending treatment after 21 days of age until disease
onset (80 days) generally led to reduced symptom severity,
although some mice developed symptoms and survived for
302–377 days of age (Williams et al., 2016). Complete withdrawal
of treatment (after 21 days of age) had a smaller effect on
lifespan, with these mice surviving for 122–132 days of age
(Williams et al., 2016).
Transactive Response DNA-Binding Protein 43
Similar to SOD1, CuATSM has also been explored as a
therapy for preventing TDP-43-associated toxicity. In SH-SY5Y
neuroblastoma cells, CuATSM protected against paraquat-
induced cell death, inhibited aggregation of TDP-43 CTFs,
and prevented stress granule formation (Parker et al., 2012).
Oral administration of CuATSM also reduced both cytoplasmic
accumulation of full-length and C-terminal fragments of TDP-43
in SOD1-G93A mice (Soon et al., 2011) suggesting this therapy
may be effective in sporadic ALS patients demonstrating
SOD1 and/or TDP-43 pathology.
Clinical Trials
CuATSM is currently under investigation in clinical trials, with
one phase I study complete (NCT02870634), a continuation
of the study ongoing (NCT04313166), and a placebo-
controlled study currently recruiting (NCT04082832) at the
time of publication.
Anti-sense Oligonucleotides
Anti-sense oligonucleotides (ASO) can bind to mRNA and
reduce protein expression, representing a potential therapeutic
strategy (Bennett and Swayze, 2010), and using ASOs targeted
at proteins such as SOD1 and TDP-43 can prevent protein
aggregation and ALS.
Superoxide Dismutase-1
Smith (2006) designed ISIS 333611, an ASO which exhibits a
high binding affinity for SOD1. Intraperitoneal injection of ISIS
333611 reduced both mRNA and protein levels of SOD1 in
transgenic rats expressing human SOD1-G93A. Also, injection
of ISIS 333611 extended the survival of transgenic SOD1-G93A
rats to 132 days, compared with rats injected with sham controls,
with a mean survival of 122 days. Finally, the transfection
of fibroblasts sourced from a human SOD1-A4V ALS patient
with ISIS 333611 demonstrated degradation of SOD1 protein
(Smith, 2006).
The ASO Tofersen, which targets and degrades SOD1mRNA,
prevented neuron loss in SOD1-G93A mice extending survival
by 40 days, and more than 50 days in SOD1-G93A rats
(McCampbell et al., 2018). Tofersen was recently used in a Phase-
I/II clinical trial, which reduced SOD1 mRNA concentrations at
the highest Tofersen concentration administered (100 mg), but
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was not sufficiently powered to report on motor improvements
or survival (Miller et al., 2020), and requires further investigation.
Transactive Response DNA-Binding Protein 43
TDP-43 is an essential protein for cellular function, therefore,
TDP-43 expression cannot be completely prevented or cell death
will occur (Sephton et al., 2012). However, some therapeutic
strategies have overcome this by targeting important interactors
of TDP-43, such as ataxin-2. Crossing an ataxin-2 deficient
mouse strain with a TDP-43 transgenic line led to reduced
TDP-43 inclusion formation, reduced stress granule formation,
and prolonged survival (Becker et al., 2017). Furthermore, a
single intracerebroventricular injection of an ASO that targets
ataxin-2 (3 µl of a 15 µg/µl) resulted in reduced ataxin-2
mRNA levels with no effect on TDP-43 mRNA expression.
However, there were reduced numbers of TDP-43 inclusions
in spinal cords, as well as improved locomotor function and
significantly increasedmean survival time (>300 days) compared
with vehicle-treated mice (29 days).
Clinical Trials
Intrathecal injection of ISIS 333611 (doses of 0.15, 0.5, 1.5, and
3 mg) over 11.5 h in phase I, randomized trial of SOD1 fALS
was demonstrated to be well tolerated, however, the therapeutic
benefits were not measured (Miller et al., 2013). With regards to
ASO targeting ataxin-2, due to the injection route chosen and the
timing of injection in mice (neonatal), the feasibility of this ASO
needs to be carefully considered.
CLR01
Protein folding in cells is dysregulated in ALS, resulting in
protein aggregation. The design of ‘‘molecular tweezers’’ that
interact with assembling proteins and acts as a pharmacological
chaperone represents a strategy to stabilize this process and
prevent aggregation (Klärner and Kahlert, 2003). The molecular
tweezer CLR01 inhibits amyloid-protein self-assembly (Fokkens
et al., 2005), is well-tolerated in mice (Attar et al., 2014), and
represents a potential therapy for ALS.
Superoxide Dismutase-1
Malik et al. (2019) demonstrated that CLR01 binds to
SOD1 and, using in vitro fibrillation assays, showed that
CLR01 treatment reduced aggregation of wild-type SOD1 as
well as mutant SOD1-E21K, SOD1-H46R, SOD1-D76Y, and
SOD1-G93A. Immunohistochemical analysis demonstrated that
CLR01 reduced SOD1 aggregates in microglia, but failed to
improve locomotor function or survival in SOD1-G93A mice
irrespective of the dose used (0.5 or 5mg/kg—daily subcutaneous
injection; Malik et al., 2019).
Transactive Response DNA-Binding Protein 43
In a recent study, Monaco et al. (2020) demonstrated that
TDP-43 is present in amyloid aggregates in a murine model of
the lysosomal storage disease mucopolysaccharidosis (MPS) type
IIIA, and aggregates could be reduced by CLR01; however, there
was no evidence of CLR01 directly interacting with TDP-43.
4,5-BIS[(N-CARBOXY METHYL
IMIDAZOLIUM)METHYLACRIDINE]
DIBROMIDE (AIM4)
Transactive Response DNA-Binding
Protein 43
Prasad et al. (2016) screened a range of acridine derivatives
to determine the effect on TDP-43 aggregation. They found
that the acridine derivative, [4,5-bis[(N-carboxy methyl
imidazolium)methylacridine] dibromide (AIM4) reduced
aggregation of C-terminal TDP-43 in yeast. A recent follow-up
study found that AIM4 could prevent the fibrillation of
purified TDP-43(194–414) (Girdhar et al., 2020). However,
further validation of the therapeutic potential and assessment
of the toxicity of this drug in vivo has not been conducted at
this time.
THERAPIES TARGETING PROTEOSTATIC
IMPAIRMENT
Arimoclomol
Superoxide Dismutase-1
Hydroxylamine derivatives are a family of compounds that
up-regulate the expression of heat shock proteins (HSPs; Vígh
et al., 1997). The hydroxylamine derivative arimoclomol differs
from other derivatives in that it up-regulates HSP expression
only in cells under stress (Hargitai et al., 2003), and works
by activating heat shock factor 1 and promoting up-regulation
of HSP70 and HSP90 (Kalmar et al., 2014). The up-regulation
of these HSPs by arimoclomol reduces SOD1 aggregation.
Intraperitoneal injection of arimoclomol into SOD1-G93A
mice improved motor neuron survival and increased mean
survival to 153 days, compared with untreated SOD1-G93A
mice (with a mean survival of 125 days; Kieran et al., 2004;
Kalmar et al., 2008). Importantly, this effect was observed
if treatment was administered early or at disease onset, and
the effect was observed regardless of sex (Kieran et al., 2004;
Kalmar et al., 2008).
Transactive Response DNA-Binding Protein 43
Activation of HIF-1 is important in maintaining the
solubility of TDP-43 and preventing aggregation, as well
as maintaining cell survival in SH-SY5Y neuroblastoma
cells (Chen et al., 2016; Lin et al., 2016). In a murine
model of TDP-43-acetylation, which causes TDP-43 to
localize in the cytosol and form inclusions, activation of
HIF-1 reduced TDP-43 inclusion formation. The authors
suggest this could be achieved with the use of arimoclomol,
however, these experiments are yet to be performed
(Wang et al., 2017).
Fused in Sarcoma
In iPSC-derived spinal motor neurons, arimoclomol was able to
retain FUS in the nucleus, and restore the DNA-damage response
in cells expressing ALS-mutant FUSR521H (Kuta et al., 2020).
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Clinical Trials
Arimoclomol has been used in clinical trials for ALS and is
well-tolerated in doses up to 200 mg thrice daily, however, the
evidence of a benefit in patients remains inconclusive (Benatar
et al., 2018). For a recent review of proteostasis-targeting
therapies in clinical trials see McAlary et al. (2019a).
Pridopidine
The Sigma-1 receptor (S1R) is an important chaperone that
prevents protein aggregation (Hong et al., 2017), suppresses
ROS production (Meunier and Hayashi, 2010), and maintains
cell survival (Hayashi and Su, 2007). S1Rs are reduced in
spinal cords of ALS patients (Prause et al., 2013), and S1R
KO mice exhibit locomotor deficiencies and MN loss (Bernard-
Marissal et al., 2015). Pridopidine is a Sigma-1 receptor agonist
(Sahlholm et al., 2015), and represents a potential therapeutic
for ALS.
Superoxide Dismutase-1
Ionescu et al. (2019) demonstrated that incubation of primary
SOD1-G93A motor neuron cultures with pridopidine reduces
MN death and restores axonal transport and MN junction
activity. Furthermore, subcutaneous administration of
pridopidine (daily, 3 or 30 mg/kg) in SOD1-G93A mice reduced
SOD1 aggregation in spinal cords, prevented muscle fiber
atrophy, and preserved NM junctions, but pridopidine treatment
alone did not lead to improved survival of SOD1-G93A mice
(Ionescu et al., 2019).
Clinical Trials
Pridopidine is well tolerated (45, 67.5, 90, and 112.5 mg taken
orally twice daily) in Huntington’s disease patients (Reilmann
et al., 2019). A clinical trial of pridopidine in ALS is set to
commence at Massachusetts General Hospital.
CONCLUSION
Years of intensive study into the disease mechanisms of
ALS strongly implicates a pathological role for both declining
proteostasis and prion-like propagation. There are intimate
links between both of these concepts that explain much of the
pathological manifestation of ALS. For example, the observation
of proteinaceous inclusions in affected tissues, the apparent
spread of pathology through neuroanatomically connected tracts,
and the preferential degeneration of motor neurons over other
cell types. SOD1 and TDP-43 can misfold and aggregate into
conformations that can propagate within and between cells in a
prion-like manner, as evidenced by the studies mentioned above
ranging from biophysical assays of protein stability to whole-
organism studies of aggregate seeding. Indeed, this knowledge of
proteostasis dysfunction and protein aggregation has led to the
development and examination of multiple therapeutics for ALS.
The questions that remain, however, are what the conformation
of these spreading strains are, the precise mechanism by which
they contribute to pathology, and if targeted therapies can be
designed to prevent their formation or spread. Also, a question
of significant importance to the field is whether FUS can spread
pathology from cell-to-cell in a pathological prion-like manner.
This knowledge would unify our understanding of the underlying
pathomechanisms in ALS.
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Şahin, A., Held, A., Bredvik, K., Major, P., Achilli, T.-M., Kerson, A. G., et al.
(2017). Human SOD1 ALS mutations in a Drosophila knock-in model cause
severe phenotypes and reveal dosage-sensitive gain- and loss-of-function
components. Genetics 205, 707–723. doi: 10.1534/genetics.116.190850
Sahlholm, K., Sijbesma, J. W. A., Maas, B., Kwizera, C., Marcellino, D.,
Ramakrishnan, N. K., et al. (2015). Pridopidine selectively occupies
sigma-1 rather than dopamine D2 receptors at behaviorally active doses.
Psychopharmacology 232, 3443–3453. doi: 10.1007/s00213-015-3997-8
Saini, A., and Chauhan, V. S. (2011). Delineation of the core aggregation
sequences of TDP-43 C-terminal fragment. Chembiochem 12, 2495–2501.
doi: 10.1002/cbic.201100427
Saini, A., and Chauhan, V. S. (2014). Self-assembling properties of peptides
derived from TDP-43 C-terminal fragment. Langmuir 30, 3845–3856.
doi: 10.1021/la404710w
San Gil, R., Ooi, L., Yerbury, J. J., and Ecroyd, H. (2017). The heat shock response
in neurons and astroglia and its role in neurodegenerative diseases. Mol.
Neurodegener. 12:65. doi: 10.1186/s13024-017-0208-6
Sangwan, S., Zhao, A., Adams, K. L., Jayson, C. K., Sawaya, M. R., Guenther, E. L.,
et al. (2017). Atomic structure of a toxic, oligomeric segment of SOD1 linked to
amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. U S A 114, 8770–8775.
doi: 10.1073/pnas.1705091114
Sarkar, M., Monteith, W. B., Wang, Y., and Pielak, G. J. (2012). Protein stability
and macromolecular crowding. Biophys. J. 102:55a. doi: 10.1016/j.bpj.2011.
11.329
Schmidt, M., Rohou, A., Lasker, K., Yadav, J. K., Schiene-Fischer, C., Fändrich, M.,
et al. (2015). Peptide dimer structure in an Aβ(1–42) fibril visualized with
cryo-EM. Proc. Natl. Acad. Sci. U S A 112, 11858–11863. doi: 10.1073/pnas.
1503455112
Schmitz, M., Cramm, M., Llorens, F., Müller-Cramm, D., Collins, S., Atarashi, R.,
et al. (2016). The real-time quaking-induced conversion assay for detection
of human prion disease and study of other protein misfolding diseases. Nat.
Protoc. 11, 2233–2242. doi: 10.1038/nprot.2016.120
Schütz, B., Reimann, J., Dumitrescu-Ozimek, L., Kappes-Horn, K., Landreth, G. E.,
Schürmann, B., et al. (2005). The oral antidiabetic pioglitazone protects
from neurodegeneration and amyotrophic lateral sclerosis-like symptoms
in superoxide dismutase-G93A transgenic mice. J. Neurosci. 25, 7805–7812.
doi: 10.1523/JNEUROSCI.2038-05.2005
Scior, A., Buntru, A., Arnsburg, K., Ast, A., Iburg, M., Juenemann, K., et al. (2018).
Complete suppression of Htt fibrilization and disaggregation of Htt fibrils
by a trimeric chaperone complex. EMBO J. 37, 282–299. doi: 10.15252/embj.
201797212
Sekhar, A., Rumfeldt, J. A. O., Broom, H. R., Doyle, C. M., Bouvignies, G.,
Meiering, E. M., et al. (2015). Thermal fluctuations of immature SOD1 lead
to separate folding and misfolding pathways. eLife 4:e07296. doi: 10.7554/eLife.
07296
Sekhar, A., Rumfeldt, J. A. O., Broom, H. R., Doyle, C. M., Sobering, R. E.,
Meiering, E. M., et al. (2016). Probing the free energy landscapes of ALS disease
mutants of SOD1 by NMR spectroscopy. Proc. Natl. Acad. Sci. U S A 113,
E6939–E6945. doi: 10.1073/pnas.1611418113
Senoo, Y., Katoh, K., Nakai, Y., Hashimoto, Y., Bando, K., and Teramoto, S.
(1988). Activity and stability of recombinant human superoxide dismutase in
buffer solutions and hypothermic perfusates. Acta Med. Okayama 42, 169–174.
doi: 10.18926/AMO/31026
Sephton, C. F., Cenik, B., Cenik, B. K., Herz, J., and Yu, G. (2012). TDP-
43 in central nervous system development and function: clues to TDP-43-
associated neurodegeneration. Biol. Chem. 393, 589–594. doi: 10.1515/hsz-2012
-0115
Shammas, S. L.,Waudby, C. A.,Wang, S., Buell, A. K., Knowles, T. P. J., Ecroyd, H.,
et al. (2011). Binding of the molecular chaperone αB-crystallin to Aβ amyloid
fibrils inhibits fibril elongation. Biophys. J. 101, 1681–1689. doi: 10.1016/j.bpj.
2011.07.056
Shelkovnikova, T. A., Peters, O. M., Deykin, A. V., Connor-Robson, N.,
Robinson, H., Ustyugov, A. A., et al. (2013). Fused in sarcoma (FUS) protein
lacking nuclear localization signal (NLS) and major RNA binding motifs
triggers proteinopathy and severe motor phenotype in transgenic mice. J. Biol.
Chem. 288, 25266–25274. doi: 10.1074/jbc.M113.492017
Shenoy, J., El Mammeri, N., Dutour, A., Berbon, M., Saad, A., Lends, A.,
et al. (2020). Structural dissection of amyloid aggregates of TDP-43 and
its C-terminal fragments TDP-35 and TDP-16. FEBS J. 287, 2449–2467.
doi: 10.1111/febs.15159
Shi, Y., Rhodes, N. R., Abdolvahabi, A., Kohn, T., Cook, N. P., Marti, A. A., et al.
(2013). Deamidation of asparagine to aspartate destabilizes Cu, Zn superoxide
dismutase, accelerates fibrillization and mirrors ALS-linked mutations. J. Am.
Chem. Soc. 135, 15897–15908. doi: 10.1021/ja407801x
Shibata, N., Hirano, A., Kobayashi, M., Asayama, K., Umahara, T., Komori, T.,
et al. (1993). Immunohistochemical demonstration of Cu/Zn superoxide
dismutase in the spinal cord of patients with familial amyotro-phic lateral
sclerosis. Acta Histochem. Cytochem. 26, 619–624.
Shimonaka, S., Nonaka, T., Suzuki, G., Hisanaga, S.-I., and Hasegawa, M. (2016).
Templated aggregation of TAR DNA-binding protein of 43 kDa (TDP-
43) by seeding with TDP-43 peptide fibrils. J. Biol. Chem. 291, 8896–8907.
doi: 10.1074/jbc.M115.713552
Shinder, G. A., Lacourse, M. C., Minotti, S., and Durham, H. D. (2001). Mutant
Cu/Zn-superoxide dismutase proteins have altered solubility and interact with
heat shock/stress proteins in models of amyotrophic lateral sclerosis. J. Biol.
Chem. 276, 12791–12796. doi: 10.1074/jbc.M010759200
Sievers, S. A., Karanicolas, J., Chang, H. W., Zhao, A., Jiang, L., Zirafi, O., et al.
(2011). Structure-based design of non-natural amino-acid inhibitors of amyloid
fibril formation. Nature 475, 96–100. doi: 10.1038/nature10154
Simpson, J. H., and Looger, L. L. (2018). Functional imaging and optogenetics
in Drosophila. Genetics 208, 1291–1309. doi: 10.1534/genetics.117.
300228
Smith, R. A. (2006). Antisense oligonucleotide therapy for neurodegenerative
disease. J. Clin. Invest. 116, 2290–2296. doi: 10.1172/JCI25424
Son, M., Puttaparthi, K., Kawamata, H., Rajendran, B., Boyer, P. J., Manfredi, G.,
et al. (2007). Overexpression of CCS in G93A-SOD1 mice leads to accelerated
neurological deficits with severe mitochondrial pathology. Proc. Natl. Acad. Sci.
U S A 104, 6072–6077. doi: 10.1073/pnas.0610923104
Soon, C. P. W., Donnelly, P. S., Turner, B. J., Hung, L. W., Crouch, P. J.,
Sherratt, N. A., et al. (2011). Diacetylbis(N(4)-methylthiosemicarbazonato)
copper(II) [CuII(atsm)] protects against peroxynitrite-induced nitrosative
damage and prolongs survival in amyotrophic lateral sclerosis mouse model.
J. Biol. Chem. 286, 44035–44044. doi: 10.1074/jbc.M111.274407
St Johnston, D. (2002). The art and design of genetic screens: Drosophila
melanogaster. Nat. Rev. Genet. 3, 176–188. doi: 10.1038/nrg751
Stack, C., Jainuddin, S., Elipenahli, C., Gerges, M., Starkova, N., Starkov, A. A.,
et al. (2014). Methylene blue upregulates Nrf2/ARE genes and
prevents tau-related neurotoxicity. Hum. Mol. Genet. 23, 3716–3732.
doi: 10.1093/hmg/ddu080
Stathopulos, P. B., Rumfeldt, J. A. O., Scholz, G. A., Irani, R. A., Frey, H. E.,
Hallewell, R. A., et al. (2003). Cu/Zn superoxide dismutase mutants associated
with amyotrophic lateral sclerosis show enhanced formation of aggregates
in vitro. Proc. Natl. Acad. Sci. U S A 100, 7021–7026. doi: 10.1073/pnas.
1237797100
Stevens, J. C., Chia, R., Hendriks, W. T., Bros-Facer, V., Van Minnen, J.,
Martin, J. E., et al. (2010). Modification of superoxide dismutase 1 (SOD1)
properties by a GFP Tag—implications for research into amyotrophic
lateral sclerosis (ALS). PLoS One 5, e9541. doi: 10.1371/journal.pone.
0009541
Strohäker, T., Jung, B. C., Liou, S.-H., Fernandez, C. O., Riedel, D., Becker, S.,
et al. (2019). Structural heterogeneity of α-synuclein fibrils amplified from
patient brain extracts. Nat. Commun. 10:5535. doi: 10.1038/s41467-019-
13564-w
Frontiers in Cellular Neuroscience | www.frontiersin.org 33 November 2020 | Volume 14 | Article 581907
McAlary et al. ALS Proteostasis and Prions
Sulston, J. E., Schierenberg, E., White, J. G., and Thomson, J. N. (1983). The
embryonic cell lineage of the nematode Caenorhabditis elegans. Dev. Biol. 100,
64–119. doi: 10.1016/0012-1606(83)90201-4
Sun, Y., Arslan, P. E., Won, A., Yip, C. M., and Chakrabartty, A. (2014). Binding of
TDP-43 to the 3′UTR of its cognatemRNA enhances its solubility. Biochemistry
53, 5885–5894. doi: 10.1021/bi500617x
Sun, C.-S., Wang, C. Y.-H., Chen, B. P.-W., He, R.-Y., Liu, G. C.-H., Wang, C.-H.,
et al. (2014). The influence of pathological mutations and proline substitutions
in TDP-43 glycine-rich peptides on its amyloid properties and cellular toxicity.
PLoS One 9:e103644. doi: 10.1371/journal.pone.0103644
Szczudlik, A., Tomik, B., Sowik, A., and Kasprzyk, K. (1998). Assessment of
the efficacy of treatment with pimozide in patients with amyotrophic lateral
sclerosis. Introductory notes. Neurol. Neurochir. Pol. 32, 821–829.
Takahashi, A., Nagao, C., Murakami, K., Kuroi, K., and Nakabayashi, T. (2020).
Effects of molecular crowding environment on the acquisition of toxic
properties of wild-type SOD1. Biochim. Biophys. Acta Gen. Subj. 1864:129401.
doi: 10.1016/j.bbagen.2019.07.010
Taylor, J. P., Brown, R. H. Jr., and Cleveland, D. W. (2016). Decoding ALS: from
genes to mechanism. Nature 539, 197–206. doi: 10.1038/nature20413
Telling, G. C., Parchi, P., Dearmond, S. J., Cortelli, P., Montagna, P., Gabizon, R.,
et al. (1996). Evidence for the conformation of the pathologic isoform of
the prion protein enciphering and propagating prion diversity. Science 274,
2079–2082. doi: 10.1126/science.274.5295.2079
Therrien, M., and Parker, J. A. (2014). Worming forward: amyotrophic lateral
sclerosis toxicity mechanisms and genetic interactions in Caenorhabditis
elegans. Front. Genet. 5:85. doi: 10.3389/fgene.2014.00085
Thorpe, J. R., Tang, H., Atherton, J., and Cairns, N. J. (2008). Fine
structural analysis of the neuronal inclusions of frontotemporal lobar
degeneration with TDP-43 proteinopathy. J. Neural Transm. 115, 1661–1671.
doi: 10.1007/s00702-008-0137-1
Tokuda, E., Nomura, T., Ohara, S., Watanabe, S., Yamanaka, K., Morisaki, Y.,
et al. (2018). A copper-deficient form of mutant Cu/Zn-superoxide dismutase
as an early pathological species in amyotrophic lateral sclerosis. Biochim.
Biophys. Acta Mol. Basis Dis. 1864, 2119–2130. doi: 10.1016/j.bbadis.2018.
03.015
Trexler, A. J., and Rhoades, E. (2012). N-Terminal acetylation is critical
for forming α-helical oligomer of α-synuclein. Protein Sci. 21, 601–605.
doi: 10.1002/pro.2056
Trist, B., Hilton, J. B., Crouch, P. J., Hare, D. J., and Double, K. L. (2020).
Superoxide dismutase 1 in health and disease: how a front-line antioxidant
becomes neurotoxic. Angew. Chem. Int. Ed Engl. doi: 10.1002/anie.202000451
[Epub ahead of print].
Tsaytler, P., Harding, H. P., Ron, D., and Bertolotti, A. (2011). Selective inhibition
of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science
332, 91–94. doi: 10.1126/science.1201396
Tsoi, P. S., Choi, K.-J., Leonard, P. G., Sizovs, A., Moosa, M. M., Mackenzie, K. R.,
et al. (2017). The N-terminal domain of ALS-linked TDP-43 assembles without
misfolding. Angew. Chem. Int. Ed Engl. 56, 12590–12593. doi: 10.1002/anie.
201706769
Turner, B. J., Atkin, J. D., Farg, M. A., Zang, D. W., Rembach, A.,
Lopes, E. C., et al. (2005). Impaired extracellular secretion of mutant
superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic
lateral sclerosis. J. Neurosci. 25, 108–117. doi: 10.1523/JNEUROSCI.4253-
04.2005
Vaccaro, A., Patten, S. A., Aggad, D., Julien, C., Maios, C., Kabashi, E., et al.
(2013). Pharmacological reduction of ER stress protects against TDP-43
neuronal toxicity in vivo. Neurobiol. Dis. 55, 64–75. doi: 10.1016/j.nbd.2013.
03.015
Vaccaro, A., Patten, S. A., Ciura, S., Maios, C., Therrien, M., Drapeau, P., et al.
(2012a). Methylene blue protects against TDP-43 and FUS neuronal toxicity
in C. elegans and D. rerio. PLoS One 7:e42117. doi: 10.1371/journal.pone.
0042117
Vaccaro, A., Tauffenberger, A., Aggad, D., Rouleau, G., Drapeau, P., and Alex
Parker, J. (2012b). Mutant TDP-43 and FUS Cause age-dependent paralysis
and neurodegeneration in C. elegans. PLoS One 7:e31321. doi: 10.1371/journal.
pone.0031321
Vaccaro, A., Tauffenberger, A., Ash, P. E. A., Carlomagno, Y., Petrucelli, L.,
and Parker, J. A. (2012c). TDP-1/TDP-43 regulates stress signaling and
age-dependent proteotoxicity in Caenorhabditis elegans. PLoS Genet.
8:e1002806. doi: 10.1371/journal.pgen.1002806
Van Damme, P., Robberecht, W., and Van Den Bosch, L. (2017). Modelling
amyotrophic lateral sclerosis: progress and possibilities. Dis. Model. Mech. 10,
537–549. doi: 10.1242/dmm.029058
Van Es, M. A., Hardiman, O., Chio, A., Al-Chalabi, A., Jeroen Pasterkamp, R.,
Veldink, J. H., et al. (2017). Amyotrophic lateral sclerosis. Lancet 390,
2084–2098. doi: 10.1016/S0140-6736(17)31287-4
Vance, C., Rogelj, B., Hortobágyi, T., De Vos, K. J., Nishimura, A. L.,
Sreedharan, J., et al. (2009). Mutations in FUS, an RNA processing protein,
cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208–1211.
doi: 10.1126/science.1165942
Vance, C., Scotter, E. L., Nishimura, A. L., Troakes, C., Mitchell, J. C., Kathe, C.,
et al. (2013). ALS mutant FUS disrupts nuclear localization and sequesters
wild-type FUS within cytoplasmic stress granules. Hum. Mol. Genet. 22,
2676–2688. doi: 10.1093/hmg/ddt117
Vaquer-Alicea, J., and Diamond, M. I. (2019). Propagation of protein
aggregation in neurodegenerative diseases. Annu. Rev. Biochem. 88, 785–810.
doi: 10.1146/annurev-biochem-061516-045049
Vargas, J. Y., Grudina, C., and Zurzolo, C. (2019). The prion-like spreading of α-
synuclein: from in vitro to in vivo models of Parkinson’s disease. Ageing Res.
Rev. 50, 89–101. doi: 10.1016/j.arr.2019.01.012
Vassall, K. A., Stubbs, H. R., Primmer, H. A., Tong, M. S., Sullivan, S. M.,
Sobering, R., et al. (2011). Decreased stability and increased formation of
soluble aggregates by immature superoxide dismutase do not account for
disease severity in ALS. Proc. Natl. Acad. Sci. U S A 108, 2210–2215.
doi: 10.1073/pnas.0913021108
Vicencio, E., Beltrán, S., Labrador, L., Manque, P., Nassif, M., and Woehlbier, U.
(2020). Implications of selective autophagy dysfunction for ALS pathology.
Cells 9:381. doi: 10.3390/cells9020381
Vieira, F. G., Hatzipetros, T., Thompson, K., Moreno, A. J., Kidd, J. D.,
Tassinari, V. R., et al. (2017). CuATSM efficacy is independently replicated
in a SOD1 mouse model of ALS while unmetallated ATSM therapy
fails to reveal benefits. IBRO Reports 2, 47–53. doi: 10.1016/j.ibror.2017.
03.001
Vígh, L., Literáti, P. N., Horváth, I., Török, Z., Balogh, G., Glatz, A.,
et al. (1997). Bimoclomol: a nontoxic, hydroxylamine derivative with stress
protein-inducing activity and cytoprotective effects. Nat. Med. 3, 1150–1154.
doi: 10.1002/JLB.4MA0820-649R
Vilchez, D., Saez, I., and Dillin, A. (2014). The role of protein clearance
mechanisms in organismal ageing and age-related diseases. Nat. Commun.
5:5659. doi: 10.1038/ncomms6659
Vivoli Vega, M., Nigro, A., Luti, S., Capitini, C., Fani, G., Gonnelli, L., et al.
(2019). Isolation and characterization of soluble human full-length TDP-43
associated with neurodegeneration. FASEB J. 33, 10780–10793. doi: 10.1096/fj.
201900474R
Walker, A. K., Farg, M. A., Bye, C. R., Mclean, C. A., Horne, M. K., and
Atkin, J. D. (2010). Protein disulphide isomerase protects against protein
aggregation and is S-nitrosylated in amyotrophic lateral sclerosis. Brain 133,
105–116. doi: 10.1093/brain/awp267
Walker, A. K., Soo, K. Y., Sundaramoorthy, V., Parakh, S., Ma, Y., Farg, M. A., et al.
(2013). ALS-associated TDP-43 induces endoplasmic reticulum stress, which
drives cytoplasmic TDP-43 accumulation and stress granule formation. PLoS
One 8:e81170. doi: 10.1371/journal.pone.0081170
Walker, D. S., Chew, Y. L., and Schafer, W. R. (2019). ‘‘Genetics of behavior in
C. elegans,’’ in The Oxford Handbook of Invertebrate Neurobiology, ed John H.
Byrne (New York, NY: Oxford University Press), 150–170.
Wang, A., Conicella, A. E., Schmidt, H. B., Martin, E. W., Rhoads, S. N.,
Reeb, A. N., et al. (2018). A single N-terminal phosphomimic disrupts TDP-43
polymerization, phase separation and RNA splicing. EMBO J. 37:e97452.
doi: 10.15252/embj.201797452
Wang, J., Farr, G. W., Hall, D. H., Li, F., Furtak, K., Dreier, L., et al.
(2009a). An ALS-linked mutant SOD1 produces a locomotor defect associated
with aggregation and synaptic dysfunction when expressed in neurons of
Caenorhabditis elegans. PLoS Genet. 5:e1000350. doi: 10.1371/journal.pgen.
1000350
Wang, J., Farr, G. W., Zeiss, C. J., Rodriguez-Gil, D. J., Wilson, J. H.,
Furtak, K., et al. (2009b). Progressive aggregation despite chaperone
Frontiers in Cellular Neuroscience | www.frontiersin.org 34 November 2020 | Volume 14 | Article 581907
McAlary et al. ALS Proteostasis and Prions
associations of a mutant SOD1-YFP in transgenic mice that develop
ALS. Proc. Natl. Acad. Sci. U S A 106, 1392–1397. doi: 10.1073/pnas.
0813045106
Wang, Y.-T., Kuo, P.-H., Chiang, C.-H., Liang, J.-R., Chen, Y.-R., Wang, S.,
et al. (2013). The truncated C-terminal RNA recognition motif of TDP-43
protein plays a key role in forming proteinaceous aggregates. J. Biol. Chem. 288,
9049–9057. doi: 10.1074/jbc.M112.438564
Wang, W.-Y., Pan, L., Su, S. C., Quinn, E. J., Sasaki, M., Jimenez, J. C., et al. (2013).
Interaction of FUS and HDAC1 regulates DNA damage response and repair in
neurons. Nat. Neurosci. 16, 1383–1391. doi: 10.1038/nn.3514
Wang, P., Wander, C. M., Yuan, C.-X., Bereman, M. S., and Cohen, T. J. (2017).
Acetylation-induced TDP-43 pathology is suppressed by an HSF1-dependent
chaperone program. Nat. Commun. 8:82. doi: 10.1038/s41467-017-
00088-4
Watson, M. D., and Lee, J. C. (2019). N-terminal acetylation affects α-synuclein
fibril polymorphism. Biochemistry 58, 3630–3633. doi: 10.1021/acs.biochem.
9b00629
Watson, M. R., Lagow, R. D., Xu, K., Zhang, B., and Bonini, N. M. (2008).
A Drosophila model for amyotrophic lateral sclerosis reveals motor neuron
damage by human SOD1. J. Biol. Chem. 283, 24972–24981. doi: 10.1074/jbc.
M804817200
Watts, J. C., and Prusiner, S. B. (2018). β-amyloid prions and the pathobiology
of Alzheimer’s disease. Cold Spring Harb. Perspect. Med. 8:a023507.
doi: 10.1101/cshperspect.a023507
Weisberg, S. J., Lyakhovetsky, R., Werdiger, A.-C., Gitler, A. D., Soen, Y., and
Kaganovich, D. (2012). Compartmentalization of superoxide dismutase 1
(SOD1G93A) aggregates determines their toxicity. Proc. Natl. Acad. Sci. U S A
109, 15811–15816. doi: 10.1073/pnas.1205829109
White, J. G., Southgate, E., Thomson, J. N., and Brenner, S. (1986). The
structure of the nervous system of the nematode Caenorhabditis elegans.
Philos. Trans. R. Soc. Lond. B Biol. Sci. 314, 1–340. doi: 10.1098/rstb.
1986.0056
White, M. A., Kim, E., Duffy, A., Adalbert, R., Phillips, B. U., Peters, O. M.,
et al. (2018). TDP-43 gains function due to perturbed autoregulation in a
Tardbp knock-in mouse model of ALS-FTD. Nat. Neurosci. 21, 552–563.
doi: 10.1038/s41593-018-0113-5
White, M. R., Mitrea, D. M., Zhang, P., Stanley, C. B., Cassidy, D. E.,
Nourse, A., et al. (2019). C9orf72 Poly(PR) dipeptide repeats disturb
biomolecular phase separation and disrupt nucleolar function. Mol. Cell 74,
713.e6–728.e6.doi: 10.1016/j.molcel.2019.03.019
Whiten, D. R., San Gil, R., Mcalary, L., Yerbury, J. J., Ecroyd, H.,
and Wilson, M. R. (2016). Rapid flow cytometric measurement of
protein inclusions and nuclear trafficking. Sci. Rep. 6:31138. doi: 10.1038/
srep31138
Williams, J. R., Trias, E., Beilby, P. R., Lopez, N. I., Labut, E. M., Samuel
Bradford, C., et al. (2016). Copper delivery to the CNS by CuATSM
effectively treats motor neuron disease in SODG93A mice co-expressing the
Copper-Chaperone-for-SOD. Neurobiol. Dis. 89, 1–9. doi: 10.1016/j.nbd.2016.
01.020
Wright, G. S. A., Antonyuk, S. V., and Hasnain, S. S. (2019). The biophysics
of superoxide dismutase-1 and amyotrophic lateral sclerosis. Q. Rev. Biophys.
52:e12. doi: 10.1017/S003358351900012X
Wright, G. S. A., Antonyuk, S. V., Kershaw, N. M., Strange, R. W., and Samar
Hasnain, S. (2013). Ligand binding and aggregation of pathogenic SOD1. Nat.
Commun. 4:1758. doi: 10.1038/ncomms2750
Wright, G. S. A., Watanabe, T. F., Amporndanai, K., Plotkin, S. S.,
Cashman, N. R., Antonyuk, S. V., et al. (2020). Purification and structural
characterization of aggregation-prone human TDP-43 involved in
neurodegenerative diseases. iScience 23:101159. doi: 10.1016/j.isci.2020.
101159
Wright, P. D., Wightman, N., Huang, M., Weiss, A., Sapp, P. C., Cuny, G. D., et al.
(2012). A high-throughput screen to identify inhibitors of SOD1 transcription.
Front. Biosci. 4, 2701–2708. doi: 10.2741/e584
Writing Group; Edaravone (MCI-186) ALS 19 Study Group. (2017).
Safety and efficacy of edaravone in well defined patients with
amyotrophic lateral sclerosis: a randomised, double-blind, placebo-
controlled trial. Lancet Neurol. 16, 505–512. doi: 10.1016/S1474-4422(17)
30115-1
Xia, G., Benmohamed, R., Kim, J., Arvanites, A. C., Morimoto, R. I.,
Ferrante, R. J., et al. (2011). Pyrimidine-2,4,6-trione derivatives and their
inhibition of mutant SOD1-dependent protein aggregation. toward a treatment
for amyotrophic lateral sclerosis. J. Med. Chem. 54, 2409–2421. doi: 10.1021/
jm101549k
Yang, L., Gal, J., Chen, J., and Zhu, H. (2014). Self-assembled FUS binds active
chromatin and regulates gene transcription. Proc. Natl. Acad. Sci. U S A 111,
17809–17814. doi: 10.1073/pnas.1414004111
Yang, C., Tan, W., Whittle, C., Qiu, L., Cao, L., Akbarian, S., et al. (2010).
The C-terminal TDP-43 fragments have a high aggregation propensity and
harm neurons by a dominant-negative mechanism. PLoS One 5:e15878.
doi: 10.1371/journal.pone.0015878
Yerbury, J. J., Farrawell, N. E., and McAlary, L. (2020). Proteome homeostasis
dysfunction: a unifying principle in ALS pathogenesis. Trends Neurosci. 43,
274–284. doi: 10.1016/j.tins.2020.03.002
Yerbury, J. J., Gower, D., Vanags, L., Roberts, K., Lee, J. A., and Ecroyd, H.
(2013). The small heat shock proteins αB-crystallin and Hsp27 suppress
SOD1 aggregation in vitro. Cell Stress Chaperones 18, 251–257.
doi: 10.1007/s12192-012-0371-1
Yerbury, J. J., Ooi, L., Dillin, A., Saunders, D. N., Hatters, D. M., Beart, P. M., et al.
(2016). Walking the tightrope: proteostasis and neurodegenerative disease.
J. Neurochem. 137, 489–505. doi: 10.1111/jnc.13575
Yoon, G., Kim, Y. K., Eom, K., and Na, S. (2013). Relationship between disease-
specific structures of amyloid fibrils and their mechanical properties. Appl.
Phys. Lett. 102:011914. doi: 10.1063/1.4774296
Yoshino, H. (2019). Edaravone for the treatment of amyotrophic lateral
sclerosis. Expert Rev. Neurother. 19, 185–193. doi: 10.1080/14737175.2019.
1581610
Yoshino, H., and Kimura, A. (2006). Investigation of the therapeutic effects of
edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase
II study). Amyotroph. Lateral Scler. 7, 241–245. doi: 10.1080/174829606008
81870
Zacco, E., Graña-Montes, R., Martin, S. R., De Groot, N. S., Alfano, C.,
Tartaglia, G. G., et al. (2019). RNA as a key factor in driving or preventing
self-assembly of the TAR DNA-binding protein 43. J. Mol. Biol. 431,
1671–1688. doi: 10.1016/j.jmb.2019.01.028
Zacco, E., Martin, S. R., Thorogate, R., and Pastore, A. (2018). The
RNA-recognition motifs of TAR DNA-binding protein 43 may play a role
in the aberrant self-assembly of the protein. Front. Mol. Neurosci. 11:372.
doi: 10.3389/fnmol.2018.00372
Zeineddine, R., Whiten, D. R., Farrawell, N. E., Mcalary, L., Hanspal, M. A.,
Kumita, J. R., et al. (2017). Flow cytometric measurement of the cellular
propagation of TDP-43 aggregation. Prion 11, 195–204. doi: 10.1080/19336896.
2017.1314426
Zhang, Y. J., Gendron, T. F., Grima, J. C., Sasaguri, H., Jansen-West, K.,
Xu, Y. F., et al. (2016). C9ORF72 poly(GA) aggregates sequester and impair
HR23 and nucleocytoplasmic transport proteins. Nat. Neurosci. 19, 668–677.
doi: 10.1038/nn.4272
Zhang, T., Mullane, P. C., Periz, G., and Wang, J. (2011). TDP-43 neurotoxicity
and protein aggregation modulated by heat shock factor and insulin/IGF-
1 signaling. Hum. Mol. Genet. 20, 1952–1965. doi: 10.1093/hmg/
ddr076
Zhang, H., Tan, C.-F., Mori, F., Tanji, K., Kakita, A., Takahashi, H.,
et al. (2008). TDP-43-immunoreactive neuronal and glial inclusions
in the neostriatum in amyotrophic lateral sclerosis with and without
dementia. Acta Neuropathol. 115, 115–122. doi: 10.1007/s00401-007-
0285-7
Zhang, X.,Wang, F., Hu, Y., Chen, R., Meng, D., Guo, L., et al. (2020). In vivo stress
granule misprocessing evidenced in a FUS knock-in ALS mouse model. Brain
143, 1350–1367. doi: 10.1093/brain/awaa076
Zhang, Y.-J., Xu, Y.-F., Cook, C., Gendron, T. F., Roettges, P., Link, C. D.,
et al. (2009). Aberrant cleavage of TDP-43 enhances aggregation and cellular
toxicity. Proc. Natl. Acad. Sci. U S A 106, 7607–7612. doi: 10.1073/pnas.
0900688106
Zheng, Z., Lauritzen, J. S., Perlman, E., Robinson, C. G., Nichols, M., Milkie, D.,
et al. (2018). A complete electron microscopy volume of the brain of adult
Drosophila melanogaster. Cell 174, 730.e22–743.e22.doi: 10.1016/j.cell.2018.
06.019
Frontiers in Cellular Neuroscience | www.frontiersin.org 35 November 2020 | Volume 14 | Article 581907
McAlary et al. ALS Proteostasis and Prions
Zhong, Y., Wang, J., Henderson, M. J., Yang, P., Hagen, B. M., Siddique, T.,
et al. (2017). Nuclear export of misfolded SOD1 mediated by a normally
buried NES-like sequence reduces proteotoxicity in the nucleus. eLife 6:e23759.
doi: 10.7554/eLife.23759
Zhou, Y., Liu, S., Liu, G., Oztürk, A., and Hicks, G. G. (2013). ALS-associated FUS
mutations result in compromised FUS alternative splicing and autoregulation.
PLoS Genet. 9:e1003895. doi: 10.1371/journal.pgen.1003895
Zhu, L., Xu, M., Yang, M., Yang, Y., Li, Y., Deng, J., et al. (2014). An
ALS-mutant TDP-43 neurotoxic peptide adopts an anti-parallel β-structure
and induces TDP-43 redistribution. Hum. Mol. Genet. 23, 6863–6877.
doi: 10.1093/hmg/ddu409
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020McAlary, Chew, Lum, Geraghty, Yerbury and Cashman. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Cellular Neuroscience | www.frontiersin.org 36 November 2020 | Volume 14 | Article 581907
